CA2666103C - Glycomimetic replacements for hexoses and n-acetyl hexosamines - Google Patents

Abstract

In one of its aspect, the present invention relates generally to compounds and methods for obtaining oligosaccharide mimics. More specifically, compounds and methods are described wherein oligosaccharide mimics are obtained by incorporating or substituting in a cyclohexane derivative. The oligosaccharide mimics have the following formula:
(see above formula) wherein R1, R2, R3, R4 and R5 have prescribed meanings. Such mimics have a variety of uses in vitro and in vivo, including as antagonists of E-selectin.

Description

GLYCOMIMETIC REPLACEMENTS FOR HEXOSES
AND N-ACETYL HEXOSAMINES
CROSS-REFERENCE TO RELATED APPLICATION
This application claims the benefit under 35 U.S.C. 119(e) of U.S. Provisional Patent Application No. 60/851,467 filed October 12, 2006.
BACKGROUND
Technical Field The present invention relates generally to compounds and methods for obtaining oligosaccharide mimics, and more particularly for obtaining oligosaccharide mimics by incorporating or substituting in a cyclohexane derivative.
Description of the Related Art Naturally occurring monosaccharides and oligosaccharides play a role, or are capable of playing 0 role, in a variety of biological processes.
In certain cases, non-naturally occurring monosaccharides and oligosaccharides may serve to replace or even improve upon their naturally occurring counterparts. Monosaccharides and particularly oligosaccharides may be difficult, and thus costly, to produce. Even where the degree of difficulty to produce is not particularly elevated, the production of monosaccharides and oligosaccharides may still nevertheless be costly. This problem is multiplied where a costly monosaccharkle or oligosaccharicie needs to be mass produced.
While mimics of monosaccharides and oligosaccharides ("glycomimetics") may improve upon their biological properties, the cost of producing the mimics may not be significantly reduced relative to that which they mimic.

Accordingly, there is a need in the art for reducing the production cost or complexity of glycomimetics. The present invention fulfills these needs and further provides other related advantages.
BRIEF SUMMARY
Briefly stated, the invention provides compounds and methods for obtaining oligosaccharide mimics. In one aspect of the present invention, a method is provided for preparing an oligosaccharide mimic comprising incorporating at least one cyclohexane derivative into an oligosaccharide or glycomimetic compound, wherein the cyclohexane derivative has the formula:
H= R2 HO

wherein, R1 = H, C1-C8 alkanyl, C1-C8 alkenyl, C1-C8 alkynyl, halogenated C1-C8 alkanyl, aryl or heteroaryl either of which may be substituted with one or more of Me, OMe, halide, OH, or NHX where X = H, C1-C8 alkanyl, C1-C8 alkenyl, C1-C8 alkynyl, halogenated C1-C8 alkanyl, aryl or heteroaryl either of which may be substituted with one or more of Me, OMe, halide, or OH; C(=0)0X, alkanyl substituted with C(=0)0X, C(=0)NHX, alkanyl substituted with C(0)NHX, where X = C1-C8 alkanyl, C1-C8 alkenyl, C1-C8 alkynyl, halogenated C1-C8 alkanyl, aryl or heteroaryl either of which may be substituted with one or more of Me, OMe, halide, or OH;
0(=0)X, OX, NHX, NH(=0)X, where X = H, C1-C8 alkanyl, C1-C8 alkenyl, C1-C8 alkynyl, halogenated C1-C8 alkanyl, aryl or heteroaryl either of which may be substituted with one or more of Me, OMe, halide, or OH;

R2 = H, C1-C8 alkanyl, C1-C8 alkenyl, C1-C8 alkynyl, halogenated C1-C8 alkanyl, aryl or heteroaryl either of which may be substituted with one or more of Me, OMe, halide, OH, or NHX where X = H, C1-C8 alkanyl, C1-C8 alkenyl, C1-C8 alkynyl, halogenated C1-C8 alkanyl, aryl or heteroaryl either of which may be substituted with one or more of Me, OMe, halide, or OH; -C(=0)0X where X is C1-C8 alkanyl, C1-C8 alkenyl, C1-C8 alkynyl, aryl or heteroaryl either of which may be substituted with one or more of Me, OMe, halide, or . OH; -C(=0)NH(CH2)nNH2 where n = 0-30, C(=0)NHX or CX2OH, where X = C1-C8 alkanyl, C1-C8 alkenyl, C1-C8 alkynyl, halogenated C1-C8 alkanyl, aryl or heteroaryl either of which may be substituted with one or more of Me, OMe, halide, or OH;
0(=0)X, OX, NHX, NH(=0)X, where X = H, C1-C8 alkanyl, C1-C8 alkenyl, C1-C8 alkynyl, halogenated C1-C8 alkanyl, aryl or heteroaryl either of which may be substituted with one or more of Me, OMe, halide, or OH; with the proviso that R1 and R2 are not both H;
the cyclohexane derivative is at least attached to the oligosaccharide or glycomimetic compound at an OH, R1 or R2. Also included are products prepared by the method.
In another aspect of the present invention, a method is provided for substituting a monosaccharide mimic for at least one hexose or hexosamine in an oligosaccharide compound or glycomimetic compound or in an oligosaccharide or glycomimetic of an oligosaccharide-containing or glycomimetic-containing compound comprising replacing at least one hexose or hexosamine in an oligosaccharide or glycomimetic compound with a cyclohexane derivative, wherein the cyclohexane derivative has the formula:

Hi R2 HO _________________________________ wherein, R1 = H, C1-C8 alkanyl, C1-C8 alkenyl, C1-C8 alkynyl, halogenated C1-C8 alkanyl, aryl or heteroaryl either of which may be substituted with one or more of Me, OMe, halide, OH, or NHX where X = H, C1-C8 alkanyl, C1-C8 alkenyl, C1-C8 alkynyl, halogenated C1-C8 alkanyl, aryl or heteroaryl either of which may be substituted with one or more of Me, OMe, halide, or OH; C(=0)0X, alkanyl substituted with C(=0)0X, C(=0)NHX, alkanyl substituted with C(0)NHX, where X = C1-C8 alkanyl, C1-C8 alkenyl, C1-C8 alkynyl, halogenated C1-C8 alkanyl, aryl or heteroaryl either of which may be substituted with one or more of Me, OMe, halide, or OH;
0(=0)X, OX, NHX, NH(=0)X, where X = H, C1-C8 alkanyl, C1-C8 alkenyl, C1-C8 alkynyl, halogenated C1-C8 alkanyl, aryl or heteroaryl either of which may be substituted with one or more of Me, OMe, halide, or OH;
R2 = H, C1-C8 alkanyl, C1-C8 alkenyl, C1-C8 alkynyl, halogenated C1-C8 alkanyl, aryl or heteroaryl either of which may be substituted with one or more of Me, OMe, halide, OH, or NHX where X = H, C1-C8 alkanyl, C1-C8 alkenyl, Cl-Ca alkynyl, halogenated C1-C8 alkanyl, aryl or heteroaryl either of which may be substituted with one or more of Me, OMe, halide, or OH; -C(=0)0X where X is C1-C8 alkanyl, C1-C8 alkenyl, C1-C8 alkynyl, aryl or heteroaryl either of which may be substituted with one or more of Me, OMe, halide, or OH; -C(=0)NH(CH2)nNH2 where n = 0-30, C(=0)NHX or CX2OH, where X = C1-C8 alkanyl, C1-C8 alkenyl, C1-C8 alkynyl, halogenated C1-C8 alkanyl, aryl or heteroaryl either of which may be substituted with one or more of Me, OMe, halide, or OH;
0(=0)X, OX, NHX, NH(=0)X, where X = H, C1-C8 alkanyl, C1-C8 alkenyl, C1-C8 alkynyl, halogenated C1-C8 alkanyl, aryl or heteroaryl either of which may be substituted with one or more of Me, OMe, halide, or OH; with the proviso that R1 and R2 are not both H;
the cyclohexane derivative is at least attached to the oligosaccharide or glycomimetic compound at an OH, R1 or R2. Also included are products prepared by the method.
In another aspect, the present invention provides an oligosaccharide or glycomimetic compound that contains at least one cyclohexane derivative, wherein the cyclohexane derivative has the formula:
H= R2 HO
W
wherein, R1 = H, C1-C8 alkanyl, C1-C8 alkenyl, C1-C8 alkynyl, halogenated C1-C8 alkanyl, aryl or heteroaryl either of which may be substituted with one or more of Me, OMe, halide, OH, or NHX where X = H, C1-C8 alkanyl, C1-C8 alkenyl, C1-C8 alkynyl, halogenated C1-C8 alkanyl, aryl or heteroaryl either of which may be substituted with one or more of Me, OMe, halide, or OH; C(=0)0X, alkanyl substituted with C(=0)0X, C(=0)NHX, alkanyl substituted with C(=0)NHX, where X = C1-C8 alkanyl, C1-C8 alkenyl, C1-C8 alkynyl, halogenated C1-C8 alkanyl, aryl or heteroaryl either of which may be substituted with one or more of Me, OMe, halide, or OH;

0(=0)X, OX, NHX, NH(=0)X, where X = H, C1-C8 alkanyl, C1-C8 alkenyl, 01-08 alkynyl, halogenated C1-C8 alkanyl, aryl or heteroaryl either of which may be substituted with one or more of Me, OMe, halide, or OH;
R2 = H, C1-C8 alkanyl, C1-C8 alkenyl, C1-C8 alkynyl, halogenated C1-C8 alkanyl, aryl or heteroaryl either of which may be substituted with one or more of Me, OMe, halide, OH, or NHX where X = H, C1-C8 alkanyl, 01-08 alkenyl, C1-C8 alkynyl, halogenated C1-C8 alkanyl, aryl or heteroaryl either of which may be substituted with one or more of Me, OMe, halide, or OH; -C(=0)0X where X is C1-C8 alkanyl, C1-C8 alkenyl, C1-C8 alkynyl, aryl or heteroaryl either of which may be substituted with one or more of Me, OMe, halide, or OH; -C(=0)NH(CH2)nNH2 where n = 0-30, C(=0)NHX or CX2OH, where X = C1-C8 alkanyl, C1-C8 alkenyl, C1-C8 alkynyl, halogenated C1-C8 alkanyl, aryl or heteroaryl either of which may be substituted with one or more of Me, OMe, halide, or OH;
0(=0)X, OX, NHX, NH(=0)X, where X = H, C1-C8 alkanyl, C1-C8 alkenyl, 01-08 alkynyl, halogenated C1-C8 alkanyl, aryl or heteroaryl either of which may be substituted with one or more of Me, OMe, halide, or OH; with the proviso that R1 and R2 are not both H;
the cyclohexane derivative is at least attached to the oligosaccharide or glycomimetic compound at an OH, R1 or R2.
In another aspect, the present invention provides a compound comprising:

R41/----Vo R2 R1 = H, C1-C8 alkanyl, C1-C8 alkenyl, C1-C8 alkynyl, halogenated C1-C8 alkanyl, aryl or heteroaryl either of which may be substituted with one or more of Me, OMe, halide, OH, or NHX where X = H, C1-C6 alkanyl, C1-C8 alkenyl, C1-C8 alkynyl, halogenated C1-C8 alkanyl, aryl or heteroaryl either of which may be substituted with one or more of Me, OMe, halide, or OH; C(=0)0X, alkanyl substituted with C(=0)0X, C(=0)NHX, alkanyl substituted with C(=0)NHX, where X = C1-C8 alkanyl, C1-C8 alkenyl, C1-C8 alkynyl, halogenated C1-C8 alkanyl, aryl or heteroaryl either of which may be substituted with one or more of Me, OMe, halide, or OH;
0(=0)X, OX, NHX, NH(=0)X, where X = H, C1-C8 alkanyl, C1-C8 alkenyl, C1-C8 alkynyl, halogenated C1-C8 alkanyl, aryl or heteroaryl either of which may be substituted with one or more of Me, OMe, halide, or OH;
R2 = H, C1-C8 alkanyl, C1-C8 alkenyl, C1-C8 alkynyl, halogenated C1-C8 alkanyl, aryl or heteroaryl either of which may be substituted with one or more of Me, OMe, halide, OH, or NHX where X = H, C1-C8 alkanyl, C1-C8 alkenyl, C1-C8 alkynyl, halogenated C1-C8 alkanyl, aryl or heteroaryl either of which may be substituted with one or more of Me, OMe, halide, or OH; -C(=0)0X where X is C1-C8 alkanyl, C1-C8 alkenyl, C1-C8 alkynyl, aryl or heteroaryl either of which may be substituted with one or more of Me, OMe, halide, or OH; -C(=0)NH(CH2)nNH2 where n = 0-30, C(=0)NHX or CX2OH, where X = C1-C8 alkanyl, C1-C8 alkenyl, C1-C8 alkynyl, halogenated C1-C8 alkanyl, aryl or heteroaryl either of which may be substituted with one or more of Me, OMe, halide, or OH;
0(=0)X, OX, NHX, NH(0)X, where X = H, C1-C8 alkanyl, C1-C8 alkenyl, C1-C8 alkynyl, halogenated C1-C8 alkanyl, aryl or heteroaryl either of which may be substituted with one or more of Me, OMe, halide, or OH; with the proviso that R1 and R2 are not both H;
n"N, NI
R3 = ¨OH, i\r // \N
N N n N--1 ¨
/ X
/
N¨N ' ¨0¨C(=0)¨X, ¨NH2, ¨NH¨C(=0)¨NHX, or ¨NH¨C(=0)¨X where n = 0-2 and X is independently selected from C1-C8 alkanyl, C1-C8 alkenyl, C1-C8 alkynyl, /N
cx1 , ' __ N/ N

i\rN 441i , Nr µ1=1 and __________________________________ (CH2)n¨COOQ where Q is H or a physiologically acceptable salt, C1-C8 alkanyl, C1-C8 alkenyl, C1-C8 alkynyl, aryl, heteroaryl, (CH2)m-aryl or (CH2)m-heteroaryl where m is 1-10, and where n = 0-10, and any of the above ring compounds may be substituted with one to three independently selected of Cl, F, CF3, C1-C8 alkoxy, NO2, C1-C8 alkanyl, C1-C8 alkenyl, C1-C8 alkynyl, C1-C14 aryl, or OY, C(0)0Y, NY2 or C(=0)NHY where Y is H, C1-C8 alkanyl, C1-C8 alkenyl, C1-C8 alkynyl, or C1-C14 aryl;
HO OH )00Q )7Q
0 _____________________________________ R4 = OH HO
ClMe 6'sulfated GIcNAc, 6'carboxylated GIcNAc, 6'sulfated GaINAc, 6'sulfated galactose, 6'carboxylated galactose, COOQ
H
where Q is H or a physiologically acceptable salt or C1-C8 alkanyl, C1-C8 alkenyl, C1-C8 alkynyl, aryl, heteroaryl, (CH2)n-aryl or (CH2)n-heteroaryl where n is 1-10, and where R9 is aryl, heteroaryl, cyclohexane, t-butane, adamantane, or triazole, and any of R9 may be substituted with one to three independently selected of Cl, F, CF3, C1-C8 alkoxy, NO2, C1-C8 alkanyl, C1-C8 alkenyl, C1-C8 alkynyl or OY, C(=0)0Y, NY2 or C(=0)NHY where Y is H, C1-C8 alkanyl, C1-C8 alkenyl, C1-C8 alkynyl or C1-C14 aryl;
or Rlo H7() where R19 is one of o o 0 o o 0 OQ 0 00 0 0 0 A ,CN A ,OH A ,N1H2 A 0 H )\SII N - - R )Slc Q )\< N H 2 )c Et N N N
HI H H H

S, V/
N N itkr AN -Ar ' 'N ickr oI
H H H H
I

O S N Me NI *OH
iN N NH OH /2 H H 0 0 \ -----C/.1 I I

v% HO,N,N HO,N,NN HO,N /N HON/
0 N*NH
)---/
,YL¨NH NFFF
OH

(CHOn A20 NH2 ANHY N)(NH2 NANHY N )LNH2 N)LNHY
AN'N
H Z Z H H

where Q is H or a physiologically acceptable salt, C1-C8 alkanyl, C1-C8 alkenyl, C1-C8 alkynyl, aryl, heteroaryl, (CH2)m-aryl or (CH2)m-heteroaryl where m is 1-10, n = 1 -4, Z and Y = Ci-C8 alkanyl, C1-C8 alkenyl, C1-C8 alkynyl, halogenated C1-C8 alkanyl, aryl and heteroaryl substituted with Me, OMe, halide, OH; and R5 = H, D-mannose, L-galactose, D-arabinose, L-fucose, polyols, X...42/6/
OH
OH
HO where X = CF3, cyclopropyl or C1-C8 alkanyl, C1-C8 alkenyl, C1-C8 alkynyl, aryl, heteroaryl, (CH2)m-aryl or (CH2)m-heteroaryl where m is 1-10, R11\Qor where Q is H or a physiologically acceptable salt, C1-C8 alkanyl, Cl-C8 alkenyl, C1-C8 alkynyl, aryl, heteroaryl, (CH2)m-aryl or (CH2)m-heteroaryl where m is 1-10, and where R11 is aryl, heteroaryl, , , , N
/

N
S\
N Nl =VI
, /
= _______________________________________________________ , or (CH2)n¨COOQ
where Q is H or a physiologically acceptable salt, C1-C8 alkanyl, C1-C8 alkenyl, C1-C8 alkynyl, aryl, heteroaryl, (CH2)m-aryl or (CH2)m-heteroaryl where m is 1-10, and where n = 0-10, and any one of the above ring compounds may be substituted with one to three independently selected of Cl, F, C1-C8 alkanyl, C1-C8 alkenyl, C1-C8 alkynyl or OY where Y is H, C1-C8 alkanyl, C1-C8 alkenyl or C1-C8 alkynyl.
The compound may include a polyethylene glycol attached thereto. Alternatively, multimers may be formed whereby the compound is attached to another of the compound by polyethylene glycol. As used herein, "another of the compound" refers to either a second compound identical to the first compound, or a second compound that is encompassed by the disclosure herein but not identical to the first compound.
In another aspect, the present invention provides a compound consisting of:

R1 = H, C1-C8 alkanyl, C1-C8 alkenyl, C1-C8 alkynyl, halogenated C1-C8 alkanyl, aryl or heteroaryl either of which may be substituted with one or more of Me, OMe, halide, OH, or NHX where X = H, C1-05 alkanyl, C1-C8 alkenyl, C1-C8 alkynyl, halogenated C1-C8 alkanyl, aryl or heteroaryl either of which may be substituted with one or more of Me, OMe, halide, or OH; C(=0)0X, alkanyl substituted with C(=0)0X, C(=0)NHX, alkanyl substituted with C(0)NHX, where X = C1-C8 alkanyl, C1-C8 alkenyl,'Ci-C8 alkynyl, halogenated C1-C8 alkanyl, aryl or heteroaryl either of which may be substituted with one or more of Me, OMe, halide, or OH;
0(=0)X, OX, NHX, NH(=0)X, where X = H, C1-C8 alkanyl, C1-C8 alkenyl, C1-C8 alkynyl, halogenated C1-C8 alkanyl, aryl or heteroaryl either of which may be substituted with one or more of Me, OMe, halide, or OH;
R2 = H, C1-C8 alkanyl, C1-C8 alkenyl, C1-C8 alkynyl, halogenated C1-C8 alkanyl, aryl or heteroaryl either of which may be substituted with one or more of Me, OMe, halide, OH, or NHX where X = H, C1-C8 alkanyl, C1-C8 alkenyl, C1-C8 alkynyl, halogenated C1-C8 alkanyl, aryl or heteroaryl either of which may be substituted with one or more of Me, OMe, halide, or OH; -C(=0)0X where X is C1-C8 alkanyl, C1-C8 alkenyl, C1-C8 alkynyl, aryl or heteroaryl either of which may be substituted with one or more of Me, OMe, halide, or OH; -C(=0)NH(CH2)nNH2 where n = 0-30, C(=0)NHX or CX2OH, where X = C1-C8 alkanyl, C1-C8 alkenyl, C1-C8 alkynyl, halogenated C1-C8 alkanyl, aryl or heteroaryl either of which may be substituted with one or more of Me, OMe, halide, or OH;
0(=0)X, OX, NHX, NH(0)X, where X = H, C1-C8 alkanyl, C1-C8 alkenyl, C1-C8 alkynyl, halogenated C1-C8 alkanyl, aryl or heteroaryl either of which may be substituted with one or more of Me, OMe, halide, or OH; with the proviso that R1 and R2 are not both H;
NN N"NN,N
R3 = ¨OH, _3( N N = ^in N
/ X
\ /
N¨N
¨0¨C(=0)¨X, ¨NH2, ¨NH¨C(=0)¨NHX, or ¨NH¨C(=0)¨X where n = 0-2 and X is independently selected from C1-C8 alkanyl, C1-C8 alkenyl, C1-C8 alkynyl, , , I
/N NN
, I I, I I, , N
/ S

=N\N N/N
Nr ____________________________________ µN
and __________________________________ (CH2)n¨COOQ where Q is H or a physiologically acceptable salt, C1-C8 alkanyl, C1-C8 alkenyl, C1-C8 alkynyl, aryl, heteroaryl, (CH2)m-aryl or (CH2)m-heteroaryl where m is 1-10, and where n = 0-10, and any of the above ring compounds may be substituted with one to three independently selected of Cl, F, CF3, Ci-C8 alkoxy, NO2, C1-C8 alkanyl, C1-C8 alkenyl, C1-C8 alkynyl, C1-C14 aryl, or OY, C(=0)0Y, NY2 or C(=0)NHY where Y is H, C1-C8 alkanyl, C1-C8 alkenyl, C1-C8 alkynyl, or C1-C14 aryl;
HO OH )C:)Q
)7Q
0 _____________________________________ R4 = OH HO
sCd*Me Cd'Me 6'sulfated GIcNAc, 6'carboxylated GIGNAc, 6'sulfated GaINAc, 6'sulfated galactose, 6'carboxylated galactose, COOQ
H
70 where Q is H or a physiologically acceptable salt or C1-C8 alkanyl, C1-C8 alkenyl, C1-C8 alkynyl, aryl, heteroaryl, (CH2)n-aryl or (CH2)n-heteroaryl where n is 1-10, and where R9 is aryl, heteroaryl, cyclohexane, t-butane, adamantane, or triazole, and any of R9 may be substituted with one to three independently selected of Cl, F, CF3, C1-C8 alkoxy, NO2, C1-C8 alkanyl, C1-C8 alkenyl, C1-C8 alkynyl or OY, C(=0)0Y, NY2 or C(=0)NHY where Y is H, C1-C8 alkanyl, C1-C8 alkenyl, C1-C8 alkynyl or C1-C14 aryl;
Or Rlo H-'70 where R1 is one of ,....S

-R -- , , ,.....S /
H - - ...-0Q -NH2 '- -0Et AN,CN )1.,NõOH
..)..., .,..NH2 N
HI H H H

_ 00 N N N'Ar *"...1(N itkr ÷ N Ar oI
H H H H
-- I
Me 0 I
OH
ON SN IsJ, N 0 0 S 0 -----Cis:
5¨. .40 N.õ1\JN HO,N/N HO....N/% HO...NN HO,N

.......:NH
)---1 F F
OH

(CH2)n A NH2 ---11-, NHY -----NANH2 ....--11-"ILNHY \ )L
N NH2 '...--N--kNHY AN--.1µ1 H Z Z H H

where Q is H or a physiologically acceptable salt, C1-C8 alkanyl, C1-C8 alkenyl, C1-C8 alkynyl, aryl, heteroaryl, (CH2)m-aryl or (CH2)m-heteroaryl where m is 1-10, n = 1 -4, Z and Y = C1-C8 alkanyl, C1-C8 alkenyl, C1-C8 alkynyl, halogenated C1-C8 alkanyl, aryl and heteroaryl substituted with Me, OMe, halide, OH; and R5 = H, D-mannose, L-galactose, D-arabinose, L-fucose, polyols, Xiremezei OH where X = CF3, cyclopropyl or C1-C8 OH
HO
alkanyl, C1-C8 alkenyl, C1-C8 alkynyl, aryl, heteroaryl, (CH2)m-aryl or (CH2)m-heteroaryl where m is 1-10, R11\
or where Q is H or a physiologically acceptable salt, C1-C8 alkanyl, C1-C8 alkenyl, C1-C8 alkynyl, aryl, heteroaryl, (CH2)m-aryl or (CH2)m-heteroaryl where m is 1-10, and where R11 is aryl, heteroaryl, I
, 40, co (N
I
N
/ 40, N
S\
N WI N2 WI it µN
, or __________________________________________________ (CH2)n¨COOQ
where Q is H or a physiologically acceptable salt, C1-C8 alkanyl, C1-C8 alkenyl, C1-C8 alkynyl, aryl, heteroaryl, (CH2)m-aryl or (CH2)m-heteroaryl where m is 1-10, and where n = 0-10, and any one of the above ring compounds may be substituted with one to three independently selected of Cl, F, C1-C8 alkanyl, C1-C8 alkenyl, C1-C8 alkynyl or OY where Y is H, C1-C8 alkanyl, C1-C8 alkenyl or C1-C8 alkynyl.
The compound may include a polyethylene glycol attached thereto. Alternatively, multimers may be formed whereby the compound is attached to another of the compound by polyethylene glycol.
In an embodiment, the present. invention provides a compound having the formula:

COOQ
OH
0 0 1111111.k 0 HO Me Jr OH

OH
HO
OH
where Q is H or a physiologically acceptable salt, and Me is methyl. The compound may include a polyethylene glycol attached thereto. Alternatively, multimers may be formed whereby the compound is attached to another of the compound by polyethylene glycol.
In an embodiment, the present invention provides a compound having the formula:
COOQ
OBz 0 0 )1111110k 0 Me ItHO
OH

OH
HO
OH
where Q is H or a physiologically acceptable salt, Me is methyl and Bz is benzoyl. The compound may include a polyethylene glycol attached thereto.
Alternatively, multimers may be formed whereby the compound is attached to another of the compound by polyethylene glycol.
In an embodiment, the present invention provides a compound having the formula:

COOQ
OBz CONH(CH2)2NH2 HO
OH Me OH
HO
OH
where Q is H or a physiologically acceptable salt, Me is methyl and Bz is benzoyl. The compound may include a polyethylene glycol attached thereto.
Alternatively, multimers may be formed whereby the compound is attached to another of the compound by polyethylene glycol.
In an embodiment, the present invention provides a compound having the formula:
HO

OBz Hd 0 0 0 VIIlk HO 0 Me HO
OH

OH
HO
OH
where Q is H or a physiologically acceptable salt, Me is methyl and Bz is benzoyl. The compound may include a polyethylene glycol attached thereto.
Alternatively, multimers may be formed whereby the compound is attached to another of the compound by polyethylene glycol.

In an embodiment, the present invention provides a compound having the formula:
HO

OH
Ha = 0 vow CONH(CH2)2M-12 HO 0 Me HO
OH

OH
HO
OH
where Q is H or a physiologically acceptable salt, and Me is methyl. The compound may include a polyethylene glycol attached thereto. Alternatively, multimers may be formed whereby the compound is attached to another of the compound by polyethylene glycol.
In an embodiment, the present invention provides a compound having the formula:
HO

OBz 0 VOL CONH(CH2)2NH2 0 =

HO 0 Me HO
OH

OH
HO
OH
where Q is H or a physiologically acceptable salt, Me is methyl and Bz is benzoyl. The compound may include a polyethylene glycol attached thereto.
Alternatively, multimers may be formed whereby the compound is attached to another of the compound by polyethylene glycol.

In an embodiment, the present invention provides a compound having the formula:
HO
HO
HO =
0 VIIIlk HO OH OH 0 Me HO
Me =
OH
OH
HO
where Me is methyl. The compound may include a polyethylene glycol attached thereto. Alternatively, multimers may be formed whereby the compound is attached to another of the compound by polyethylene glycol.
In an embodiment, the present invention provides a compound having the formula:
COOQ
OBz 0 11.11k COO Me HO
OH Me HO
OH
where Q is H or a physiologically acceptable salt, Me is methyl and Bz is benzoyl. The compound may include a polyethylene glycol attached thereto.
Alternatively, multimers may be formed whereby the compound is attached to another of the compound by polyethylene glycol.
In an embodiment, the present invention provides a compound having the formula:

COOQ
OBz = =
NI^ Me = Me tHO
OH
=
OH
HO
OH
where Q is H or a physiologically acceptable salt, Me is methyl and Bz is benzoyl. The compound may include a polyethylene glycol attached thereto.
Alternatively, multimers may be formed whereby the compound is attached to another of the compound by polyethylene glycol.
In an embodiment, the present invention provides a compound having the formula:
COOQ
OH
0 ----7\0 COO Me 0 Me Jr HO
OH

OH
HO
OH
where Q is H or a physiologically acceptable salt, and Me is methyl. The compound may include a polyethylene glycol attached thereto. Alternatively, multimers may be formed whereby the compound is attached to another of the compound by polyethylene glycol.
In an embodiment, the present invention provides a compound having the formula:

HO

OBz V.111L COOMe HO 0 Me HO
OH

OH
HO
OH
where Q is H or a physiologically acceptable salt, Me is methyl and Bz is benzoyl. The compound may include a polyethylene glycol attached thereto.
Alternatively, multimers may be formed whereby the compound is attached to another of the compound by polyethylene glycol.
In an embodiment, the present invention provides a compound having the formula:
HO
tOH

OH

VOL COOMe HO 0 Me HO
OH

OH
HO
OH
where Q is H or a physiologically acceptable salt, and Me is methyl. The compound may include a polyethylene glycol attached thereto. Alternatively, multimers may be formed whereby the compound is attached to another of the compound by polyethylene glycol.

In an embodiment, the present invention provides a compound having the formula:
COOEt OBz 00H 0 0?kie OH
ki OH
where Me is methyl, Et is ethyl, and Bz in benzoyl. The compound may include a polyethylene glycol attached thereto. Alternatively, multimers may be formed whereby the compound is attached to another of the compound by polyethylene glycol.
In an embodiment, the present invention provides a compound having the formula:
?H

OBz 0 Me OH
Jr OH k2 ..)._ OH
where Me is methyl and Bz in benzoyl. The compound may include a polyethylene glycol attached thereto. Alternatively, multimers may be formed whereby the compound is attached to another of the compound by polyethylene glycol.
In an embodiment, the present invention provides a compound having the formula:

COOEt OBz 0 / _s-..'Me 0 --- \---1 07-79Lr 0 Me OH 1..1 Fi where Me is methyl, Et is ethyl and Bz is benzoyl. The compound may include a polyethylene glycol attached thereto. Alternatively, multimers may be formed whereby the compound is attached to another of the compound by polyethylene glycol.
In an embodiment, the present invention provides a compound having the formula:
OH
I

OBz 0 0 ot5:1µAe r 0 Me Ar OH

fi where Me is methyl and Bz is benzoyl. The compound may include a polyethylene glycol attached thereto. Alternatively, multimers may be formed whereby the compound is attached to another of the compound by polyethylene glycol.
These and other aspects of the present invention will become apparent upon reference to the following detailed description and-attached drawings.

BRIEF DESCRIPTION OF THE SEVERAL VIEWS OF THE DRAWINGS
Figure 1 is a diagram illustrating the synthesis of GIcNAc mimics from tetrahydrophthalic anhydride.
Figure 2 is a diagram illustrating the synthesis of GIcNAc mimics from cyclohexenon.
Figure 3 is a diagram illustrating the synthesis of mimics.
Figure 4 is a diagram illustrating the synthesis of mimics.
Figure 5 is a diagram illustrating the synthesis of mimics.
Figure 6 is a diagram illustrating the synthesis of mimics.
Figure 7 is a diagram illustrating the synthesis of mimics.
Figure 8 is a diagram illustrating the synthesis of mimics.
Figure 9 is a diagram illustrating the synthesis of mimics.
Figure 10 is a diagram illustrating the synthesis of a pegylated mimic.
Figure 11 is a diagram illustrating the synthesis of a pegylated tetramer of a mimic.
Figure 12 is a diagram illustrating the synthesis of mimics.
Figure 13 is a diagram illustrating the synthesis of mimics.
DETAILED DESCRIPTION
As noted above, the present invention provides compounds and methods for obtaining monosaccharide and oligosaccharide mimics. Such mimics have a variety of uses in vitro and in vivo, including as antagonists of E-selectin.
Within the present invention, an oligosaccharide mimic may be prepared by incorporating one or more cyclohexane derivatives into an oligosaccharide or glycomimetic compound. An oligosaccharide refers to two or more monosaccharides covalently joined. Oligosaccharides are polymers containing monosaccharide units, typically with 2 to about 100 monosaccharides and any integer in-between. Each monosaccharide of an oligosaccharide is independently selected; although two or more monosaccharides may be identical.
The cyclohexane derivative of the methods of the present invention has the formula:
H = R2 HO

R1 may be H, C1-C8 alkanyl, C1-C8 alkenyl, C1-C8 alkynyl, halogenated C1-C8 alkanyl, aryl or heteroaryl either of which may be substituted with one or more of Me, OMe, halide, OH, or NHX where X = H, C1-C8 alkanyl, C1-C8 alkenyl, C1-C8 alkynyl, halogenated C1-C8 alkanyl, aryl or heteroaryl either of which may be substituted with one or more of Me, OMe, halide, or OH; C(=0)0X, alkanyl substituted with C(=0)0X, C(=0)NHX, alkanyl substituted with C(=0)NHX, where X = Ci-C8 alkanyl, C1-C8 alkenyl, C1-C8 alkynyl, halogenated C1-C8 alkanyl, aryl or heteroaryl either of which may be substituted with one or more of Me, OMe, halide, or OH; 0(=0)X, OX, NHX, NH(=0)X, where X = H, C1-C8 alkanyl, C1-C8 alkenyl, C1-C8 alkynyl, halogenated C1-C8 alkanyl, aryl or heteroaryl either of which may be substituted with one or more of Me, OMe, halide, or OH. R2 may be H, C1-C8 alkanyl, C1-C8 alkenyl, C1-C8 alkynyl, halogenated C1-C8 alkanyl, aryl or heteroaryl either of which may be substituted with one or more of Me, OMe, halide, OH, or NHX where X = H, C1-C8 alkanyl, C1-C8 alkenyl, C1-C8 alkynyl, halogenated C1-C8 alkanyl, aryl or heteroaryl either of which may be substituted with one or more of Me, OMe, halide, or OH;

-C(=0)0X where X is C1-C8 alkanyl, C1-C8 alkenyl, C1-C8 alkynyl, aryl or heteroaryl either of which may be substituted with one or more of Me, OMe, halide, or OH; -C(=0)NH(CH2)nNH2 where n = 0-30, C(0)NHX or CX2OH, where X = C1-C8 alkanyl, C1-C8 alkenyl, C1-C8 alkynyl, halogenated C1-C8 alkanyl, aryl or heteroaryl either of which may be substituted with one or more of Me, OMe, halide, or OH; 0(=0)X, OX, NHX, NH(=0)X, where X = H, C1-C8 alkanyl, C1-C8 alkenyl, C1-C8 alkynyl, halogenated C1-C8 alkanyl, aryl or heteroaryl either of which may be substituted with one or more of Me, OMe, halide, or OH; with the proviso that R1 and R2 are not both H. The cyclohexane derivative is attached to the oligosaccharide or glycomimetic compound at least Such a cyclohexane derivative may also be used in a method for substituting a monosaccharide mimic (a cyclohexane derivative) for at least one hexose or hexosamine. The hexose or hexosamine may be in an oligosaccharide or glycomimetic compound or in an oligosaccharide or glycomimetic possessed by an oligosaccharide-containing or glycomimetic-As used herein, a "C1-C8 alkanyl" refers to an alkane substituent with one to eight carbon atoms and may be straight chain, branched or cyclic (cycloalkanyl). Examples are methyl, ethyl, propyl, isopropyl, butyl and t-butyl.
A "halogenated C1-C8 alkanyl" refers to a "C1-C8 alkanyl" possessing at least one halogen. Where there is more than one halogen present, the halogens carbon-carbon triple bond, and may be straight chain, branched or cyclic (cycloalkynyl). Examples are similar to "C1-C8 alkanyl" examples except possessing at least one carbon-carbon triple bond. An "alkoxy" refers to an oxygen substituent possessing a "C1-C8 alkanyl," "C1-C8 alkenyl" or "C1-C8 alkynyl." This is -0-alkyl; for example methoxy, ethoxy, n-propoxy, i-propoxy, n-butoxy and the like; and alkenyl or alkynyl variations thereof (except for methoxy). It further refers to the group 0-alkyl-W-alkyl where W is 0 or N;
for example -0-(CH2)n-W-(CH2)m where n and m are independently 1-10. An "aryl"
refers to an aromatic substituent with one to fourteen carbon atoms in one or multiple rings which may be separated by a bond or fused. A "heteroaryl" is similar to an "aryl" except the aromatic substituent possesses at least one heteroatom (such as N, 0 or S) in place of a ring carbon. Examples of aryls and heteroaryls include phenyl, naphthyl, pyridinyl, pyrimidinyl, triazolo, furanyl, oxazolyl, thiophenyl, quinolinyl and diphenyl. As used herein, the term "independently selected" refers to the selection of identical or different substituents. "Me" and "Et" represent methyl and ethyl, respectively. "Bz"
represents benzoyl. "Ar" represents aryl. Examples of physiologically acceptable salts include Na, K, Li, Mg and Ca. Monosaccharide substituents recited herein (e.g., D-mannose, L-galactose, D-arabinose and L-fucose) may be in the furanose, pyranose or open form.
A linker arm may be desirable for attachment, for example, to a monosaccharide, a monosaccharide mimic or something else such as an amino acid, nucleic acid or lipid. A linker may include a spacer group, such as ¨(CH2)n¨ or ¨0(CH2)n¨ where n is generally about 1-20 (all number ranges disclosed herein include any whole integer range therein). An example of a linker is ¨NH2, e.g., ¨CH2¨NH2 when it includes a short spacer group.
Embodiments of linkers include the following:

HSH
),( I I
¨N¨C¨N¨

Et0 OEt Squaric acid Thiourea Et0 OEt N
(0)n Dithiadiazoleoxide Acylation via Thiofuran HO HO OH
I II I II II i ¨N¨C¨(CH2)2¨CH2¨NH¨ ¨N¨C¨(CH2)n¨C¨N¨

N-Pentenoylation and Coupling via bifunctional Reductive amination NHS reagent Other linkers with or without a spacer group (e.g., CONH(CH2)2NH2, COOMe, or polyethylene glycol or derivative) will be familiar to those in the art or in possession of the present disclosure.
Alternatively, or in combination with a linker arm, a cyclohexane derivative may be attached at one or both OH.
The methods of the present invention provide for a variety of compounds. For example, in one embodiment is provided an oligosaccharide or glycomimetic compound that contains at least one cyclohexane derivative, wherein the cyclohexane derivative has the formula:

HO 114.11k R2 HO

wherein, R1 is defined as above;
R2 is defined as above; and the cyclohexane derivative is at least attached to the oligosaccharide or glycomimetic compound at an OH, R1 or R2.
In another embodiment is provided a compound comprising:

HO ( R1 R1 of the formula may be H, C1-C8 alkanyl, C1-C8 alkenyl, C1-C8 alkynyl, halogenated C1-C8 alkanyl, aryl or heteroaryl either of which may be substituted with one or more of Me, OMe, halide, OH, or NHX where X = H, C1-C8 alkanyl, C1-C8 alkenyl, C1-C8 alkynyl, halogenated C1-C8 alkanyl, aryl or heteroaryl either of which may be substituted with one or more of Me, OMe, halide, or OH; C(=0)0X, alkanyl substituted with C(0)OX, C(0)NHX, alkanyl substituted with C(=0)NHX, where X = C1-C8 alkanyl, C1-C8 alkenyl, C1-C8 alkynyl, halogenated C1-C8 alkanyl, aryl or heteroaryl either of which may be substituted with one or more of Me, OMe, halide, or OH; 0(=0)X, OX, NHX, NH(=0)X, where X = H, C1-C8 alkanyl, Cl-C8 alkenyl, C1-C8 alkynyl, halogenated C1-C8 alkanyl, aryl or heteroaryl either of which may be substituted with one or more of Me, OMe, halide, or OH;

R2 of the formula may be H, C1-C8 alkanyl, C1-C8 alkenyl, C1-C8 alkynyl, halogenated C1-C8 alkanyl, aryl or heteroaryl either of which may be substituted with one or more of Me, OMe, halide, OH, or NHX where X = H, C1-C8 alkanyl, C1-C8 alkenyl, C1-C8 alkynyl, halogenated C1-C8 alkanyl, aryl or heteroaryl either of which may be substituted with one or more of Me, OMe, halide, or OH; -C(=0)0X where X is C1-C8 alkanyl, C1-C8 alkenyl, C1-C8 alkynyl, aryl or heteroaryl either of which may be substituted with one or more of Me, OMe, halide, or OH; -C(=0)NH(CH2)nNI-12 where n = 0-30, C(=0)NHX or CX2OH, where X = C1-C8 alkanyl, C1-C8 alkenyl, C1-C8 alkynyl, halogenated C1-C8 alkanyl, aryl or heteroaryl either of which may be substituted with one or more of Me, OMe, halide, or OH; 0(=0)X, OX, NHX, NH(=0)X, where X = H, C1-C8 alkanyl, C1-C8 alkenyl, Ci-C8 alkynyl, halogenated Cl-C8 alkanyl, aryl or heteroaryl either of which may be substituted with one or more of Me, OMe, halide, or OH; with the proviso that R1 and R2 are not both H;
NN N, NN N
R3 of the formula may be ¨OH, N, 1\1 N NI!NX
\NJ( \N-1/=1 ' / X /
¨0¨C(=0)¨X, ¨NH2, ¨NH¨C(=0)¨NHX, or ¨NH¨C(=0)¨X where n = 0-2 and X is independently selected from C1-C8 alkanyl, C1-C8 alkenyl, C1-C8 alkynyl, 44, , , el /N N
, N/ /1\>
411 NµN = , NI( µ1\1 and ______________________________________ (CH2)n¨COOQ where Q is H or a physiologically acceptable salt, C1-C8 alkanyl, C1-C8 alkenyl, C1-C8 alkynyl, aryl, heteroaryl, (CH2)m-aryl or (CH2)m-heteroaryl where m is 1-10, and where n = 0-10, and any of the above ring compounds may be substituted with one to three independently selected of Cl, F, CF3, C1-C8 alkoxy, NO2, C1-C8 alkanyl, C1-C8 alkenyl, C1-C8 alkynyl, C1-C14 aryl, or OY, C(=0)0Y, NY2 or C(=0)NHY where Y is H, C1-C8 alkanyl, C1-C8 alkenyl, C1-C8 alkynyl, or C1-C14 aryl;

R4 of the formula may be 0 = H HO
)Me )1COQ
C;dMe 6'sulfated GIcNAc, 6'carboxylated GIcNAc, 6'sulfated GaINAc, 6'sulfated galactose, 6'carboxylated galactose, COOQ
H
0 where Q is H or a physiologically acceptable salt or C1-C8 alkanyl, C1-C8 alkenyl, C1-C8 alkynyl, aryl, heteroaryl, (CH2)n-aryl or (CH2)n-heteroaryl where n is 1-10, and where R9 is aryl, heteroaryl, cyclohexane, t-butane, adamantane, or triazole, and any of R9 may be substituted with one to three independently selected of Cl, F, CF3, C1-C8 alkoxy, NO2, C1-C8 alkanyl, C1-C8 alkenyl, C1-C8 alkynyl or OY, C(=0)0Y, NY2 or C(=0)NHY where Y is H, C1-C8 alkanyl, C1-C8 alkenyl, C1-C8 alkynyl or Cl-C14 aryl;
or H

where R1 is one of AO
S, R ,,,S /
/
H - NI". - OQ -NH2 '' -0Et AN,CN AN,OH AN,NH2 HI H H H
OQ

\ A \\S
S S
N N itkr '''N -Ar N Akr 0+
H H H H

Me NI OH
(:1 0 S 0 ------(4 ----141 e5r OH OH /2 ¨NH ..-----NH 0 N(14N HO,N,N HO.....v% HO....NN HO,N

N.\NH
)---j OH

(CH2)n H Z Z H H
where Q is H or a physiologically acceptable salt, C1-C8 alkanyl, C1-C8 alkenyl, C1-C8 alkynyl, aryl, heteroaryl, (CH2)m-aryl or (CH2)m-heteroaryl where m is 1-10, n = 1 -4, Z and Y = C1-C8 alkanyl, C1-C8 alkenyl, C1-C8 alkynyl, halogenated C1-C8 alkanyl, aryl and heteroaryl substituted with Me, OMe, halide, OH; and R5 of the formula may be H, D-mannose, L-galactose, D-arabinose, X
polyols, L-fucose, where X = CF3, cyclopropyl OH
HO
or C1-C8 alkanyl, C1-C8 alkenyl, C1-C8 alkynyl, aryl, heteroaryl, (CH2)m-aryl or (CH2)m-heteroaryl where m is 1-10, R11\Qor where Q is H or a physiologically acceptable salt, C1-C8 alkanyl, C1-C8 alkenyl, C1-C8 alkynyl, aryl, heteroaryl, (CH2)m-aryl or (CH2)m-heteroaryl where m is 1-10, and where R11 is aryl, heteroaryl, , I , , N cl / , , ,N,;
NrN
µN
10 , or _________________ (CH2)n¨COOQ
where Q is H or a physiologically acceptable salt, C1-C8 alkanyl, C1-C8 alkenyl, C1-C8 alkynyl, aryl, heteroaryl, (CH2)m-aryl or (CH2)m-heteroaryl where m is 1-10, and where n = 0-10, and any one of the above ring compounds may be substituted with one to three independently selected of Cl, F, C1-C8 alkanyl, C1-C8 alkenyl, C1-C8 alkynyl or OY where Y is H, C1-C8 alkanyl, C1-C8 alkenyl or C1-C8 alkynyl.
In another embodiment is provided a compound consisting of:

R4/4\ 2 R1 is H, C1-C8 alkanyl, C1-C8 alkenyl, C1-C8 alkynyl, halogenated C1-C8 alkanyl, aryl or heteroaryl either of which may be substituted with one or more of Me, OMe, halide, OH, or NHX where X = H, C1-C8 alkanyl, C1-C8 alkenyl, C1-C8 alkynyl, halogenated C1-C8 alkanyl, aryl or heteroaryl either of which may be substituted with one or more of Me, OMe, halide, or OH; C(=0)0X, alkanyl substituted with C(=0)0X, C(0)NHX, alkanyl substituted with C(0)NHX, where X = C1-C8 alkanyl, C1-C8 alkenyl, C1-C8 alkynyl, halogenated C1-C8 alkanyl, aryl or heteroaryl either of which may be substituted with one or more of Me, OMe, halide, or OH;
0(=0)X, OX, NHX, NH(=0)X, where X = H, C1-C8 alkanyl, C1-C8 alkenyl, C1-C8 alkynyl, halogenated C1-C8 alkanyl, aryl or heteroaryl either of which may be substituted with one or more of Me, OMe, halide, or OH;
R2 is H, C1-C8 alkanyl, C1-C8 alkenyl, C1-C8 alkynyl, halogenated C1-C8 alkanyl, aryl or heteroaryl either of which may be substituted with one or more of Me, OMe, halide, OH, or NHX where X = H, C1-C8 alkanyl, C1-C8 alkenyl, C1-C8 alkynyl, halogenated C1-C8 alkanyl, aryl or heteroaryl either of which may be substituted with one or more of Me, OMe, halide, or OH; -C(=0)0X where X is C1-C8 alkanyl, C1-C8 alkenyl, C1-C8 alkynyl, aryl or heteroaryl either of which may be substituted with one or more of Me, OMe, halide, or OH; -C(=0)NH(CH2)nNH2 where n = 0-30, C(=0)NHX or CX2OH, where X = C1-C8 alkanyl, C1-C8 alkenyl, C1-C8 alkynyl, halogenated C1-C8 alkanyl, aryl or heteroaryl either of which may be substituted with one or more of Me, OMe, halide, or OH;
0(=0)X, OX, NHX, NH(=0)X, where X = H, C1-C8 alkanyl, C1-C8 alkenyl, C1-C8 alkynyl, halogenated C1-C8 alkanyl, aryl or heteroaryl either of which may be substituted with one or more of Me, OMe, halide, or OH; with the proviso that R1 and R2 are not both H;
1\( rµ, VNI

r.v N
R3 is ¨OH, \kJ/ .-/\
N
N
/N/
/ X
\ /
N¨N
¨0¨C(=0)¨X, ¨NH2, ¨NH¨C(=0)¨NHX, or ¨NH¨C(=0)¨X where n = 0-2 and X is independently selected from C1-C8 alkanyl, C1-C8 alkenyl, C1-C8 alkynyl, , , el N CX) , I , , N
HN
1101 N , z / =
N
and ______________________________________ (CH2)n¨COOQ where Q is H or a physiologically acceptable salt, C1-C8 alkanyl, C1-C8 alkenyl, C1-C8 alkynyl, aryl, heteroaryl, (CH2)nraryl or (CH2)m-heteroaryl where m is 1-10, and where n = 0-10, and any of the above ring compounds may be substituted with one to three independently selected of Cl, F, CF3, C1-C8 alkoxy, NO2, C1-C8 alkanyl, C1-C8 alkenyl, C1-C8 alkynyl, C1-C14 aryl, or OY, C(=0)0Y, NY2 or C(=0)NHY where Y is H, C1-C8 alkanyl, C1-C8 alkenyl, C1-C8 alkynyl, or C1-C14 aryl;
HO
0 _________________________________________________ 0 ___ R4 is OH HO Ei> FK) Cd=Me 6'sulfated GIcNAc, 6'carboxylated GIcNAc, 6'sulfated GaINAc, 6'sulfated galactose, 6'carboxylated galactose, COOQ
H r/
0 where Q is H or a physiologically acceptable salt or Cl-C8 alkanyl, C1-C8 alkenyl, C1-C8 alkynyl, aryl, heteroaryl, (CH2)n-aryl or (CH2)n-heteroaryl where n is 1-10, and where R9 is aryl, heteroaryl, cyclohexane, t-butane, adamantane, or triazole, and any of R9 may be substituted with one to three independently selected of Cl, F, CF3, Ci-C8 alkoxy, NO2, C1-C8 alkanyl, C1-C8 alkenyl, C1-C8 alkynyl or OY, C(=0)0Y, NY2 or C(=0)NHY where Y is H, C1-C8 alkanyl, Ci-C8 alkenyl, Ci-C8 alkynyl or C1-C14 aryl;
or Rlo where R1 is one of AOH NR S/(0Q <NH2 0Et A )\13/
,CN ),OH A N,N1H2 N N
HI H H H
.\\s"
-N N i!kr N itkr 1\1 Akr O
H H H H
I
Me 0 NI OH

/20 s_. *

N'NHO,N,INL HO,N,NN

N\NH
)\-41 ¨N
OH

(CH2)n 'NANHY 'NANH2 'N)(NHY AN'N
where Q is H or a physiologically acceptable salt, C1-C8 alkanyl, C1-C8 alkenyl, C1-C8 alkynyl, aryl, heteroaryl, (CH2)m-aryl or (CH2)m-heteroaryl where m is 1-10, n = 1 -4, Z and Y = C1-C8 alkanyl, C1-C8 alkenyl, C1-C8 alkynyl, halogenated Cl-C8 alkanyl, aryl and heteroaryl substituted with Me, OMe, halide, OH; and R5 is H, D-mannose, L-galactose, D-arabinose, L-fucose, polyols, OH where X = CF3, cyclopropyl or C1-C8 OH
HO
alkanyl, C1-C8 alkenyl, C1-C8 alkynyl, aryl, heteroaryl, (CH2)m-aryl or (CH2)m-heteroaryl where m is 1-10, R11\Q, or where Q is H or a physiologically acceptable salt, C1-C8 alkanyl, C1-C8 alkenyl, C1-C8 alkynyl, aryl, heteroaryl, (CH2)m-aryl or (CH2)m-heteroaryl where m is 1-10, and where R11 is aryl, heteroaryl, 1 Apo , 0 I*
1101 N Ne, \N , , or ___________________________________________________ (CH2)n¨COOQ
where Q is H or a physiologically acceptable salt, C1-C8 alkanyl, Ci-c8alkenyl, C1-C8 alkynyl, aryl, heteroaryl, (CH2)m-aryl or (CH2)m-heteroaryl where m is 1-10, and where n = 0-10, and any one of the above ring compounds may be substituted with one to three independently selected of Cl, F, C1-C8 alkanyl, C1-C8 alkenyl, C1-C8 alkynyl or OY where Y is H, C1-C8 alkanyl, C1-C8 alkenyl or C1-C8 alkynyl.
In another embodiment is provided a compound having the formula:

COOQ
OH

0 Me HO
OH

OH
HO
OH
where Q is H or a physiologically acceptable salt, and Me is methyl.
In another embodiment is provided a compound having the formula:
COOQ
OBz 0 011111k 0 Me HO
OH

OH
HO
OH
where Q is H or a physiologically acceptable salt, Me is methyl and Bz is benzoyl.
In another embodiment is provided a compound having the formula:

COOQ
OBz CONH(CH2)2NH2 0 Iff HO
OH
0 Me OH
HO
OH
where Q is H or a physiologically acceptable salt, Me is methyl and Bz is benzoyl.
In another embodiment is provided a compound having the formula:
HO

OBz Hd 0 0 0 1111 HO 0 Me HO
OH

OH
HO
OH
where Q is H or a physiologically acceptable salt, Me is methyl and Bz is benzoyl.
In another embodiment is provided a compound having the formula:

HO
\ _____________ tµOH
\, CO2Q
OH
HO- 0 = o INOWCONH(CH2)2NH2 H HO 0 Me HO
OH

OH
HO
OH
where Q is H or a physiologically acceptable salt, and Me is methyl.
In another embodiment is provided a compound having the formula:
HO
\ '31-1 OBz HO- 0 0 0 0 CONH(CH2)2M-12 H HO Me HO
OH

OH
HO
OH
where Q is H or a physiologically acceptable salt, Me is methyl and Bz is benzoyl.
In another embodiment is provided a compound having the formula:

HO
=
H= HO 0 1111 HO OH 0 Me HO M-OH =
OH
OH
HO
where Me is methyl.
In an embodiment, the present invention provides a compound having the formula:
COOQ
OBz 0 look COO Me HO
OH Me OH
HO
OH
where Q is H or a physiologically acceptable salt, Me is methyl and Bz is benzoyl.
In an embodiment, the present invention provides a compound having the formula:

COOQ
OBz = look Me =

= Me IHO
OH
=
OH
HO
OH
where Q is H or a physiologically acceptable salt, Me is methyl and Bz is benzoyl.
In an embodiment, the present invention provides a compound having the formula:
COOQ
OH
0 110illk COOMe AtillIf HO
OH
0 Me OH
HO
OH
where Q is H or a physiologically acceptable salt, and Me is methyl.
In an embodiment, the present invention provides a compound having the formula:

HO
\ C11-1 OBz HO' 0 0 I-7\0 ImoIlk COOMe H HO 0 Me HO
OH

OH
HO
OH
where Q is H or a physiologically acceptable salt, Me is methyl and Bz is benzoyl.
In an embodiment, the present invention provides a compound having the formula:
HO
\ 1:31H

OH
HO- 0 0 0 ViIIILCOOMe H HO 0 Me HO
OH

OH
HO
OH
where Q is H or a physiologically acceptable salt, and Me is methyl.
In an embodiment, the present invention provides a compound having the formula:
COOEt OBz Me /
O H ::51 OH
OH
OR

where Me is methyl, Et is ethyl, and Bz in benzoyl. The compound may include a polyethylene glycol attached thereto. Alternatively, multimers may be formed whereby the compound is attached to another of the compound by polyethylene glycol.
In an embodiment, the present invention provides a compound having the formula:
?H

OH H
I OBz ----17--,..).-OH Me where Me is methyl and Bz in benzoyl. The compound may include a polyethylene glycol attached thereto. Alternatively, multimers may be formed whereby the compound is attached to another of the compound by polyethylene glycol.
In an embodiment, the present invention provides a compound having the formula:
COOEt OBz /00H _________________________________ 0 c(ovie Me OH kc.2...)....
OH
where Me is methyl, Et is ethyl and Bz is benzoyl. The compound may include a polyethylene glycol attached thereto. Alternatively, multimers may be formed whereby the compound is attached to another of the compound by polyethylene glycol.

In an embodiment, the present invention provides a compound having the formula:
OH

OBz 0 i\lie JOH 0 Me OH
"" OH
where Me is methyl and Bz is benzoyl. The compound may include a polyethylene glycol attached thereto. Alternatively, multimers may be formed whereby the compound is attached to another of the compound by polyethylene glycol.
For the compounds described herein, a free acid substituent, e.g., CO2H and (0=)S(=0)0H, encompasses a sodium salt of the acid, e.g., COONa and (0=)S(=0)0Na, and vice versa. Furthermore, a sodium salt of the acid is merely representative and any physiologically acceptable acid salt (e.g., Li, K, Mg and Ca) is encompassed. In addition, for the compounds described herein, a free acid substituent (or salt thereof) may be modified as an ester (e.g., alkanyl ester) or as an amide or amide-like (e.g., CONHOH).
For the compounds described herein (both generically and specifically), a polyethylene glycol (PEG), including derivatives thereof, may be attached to a compound. Alternatively, multimers of the same compound or different compounds of the compounds described herein (i.e., two or more compounds joined to one another) may be formed using PEG. Examples of particular compounds amenable to the attachment of a PEG or to the formation of a multimer including PEG, are disclosed above as embodiments of the present invention. Procedures for preparing a pegylated compound or pegylated multimers will be familiar to those in the art or in possession of the present disclosure. Examples are depicted in Figure 10 (a pegylated compound) and Figure 11 (a pegylated tetramer).
The following Examples are offered by way of illustration and not by way of limitation.
EXAMPLES

SYNTHESIS OF G1cNAc MIMIC FROM TETRAHYDROPHTHALIC ANHYDRIDE (Fig. 1) Synthesis of intermediate 1:
Amberlyste 15 (50.0 g) was placed in a flask and dried in high vacuo for 1 h. Methanol (11) was added, followed by cis-1,2,3,6-tetrahydrophthalic anhydride (50.0 g, 328 mmol) and trimethylorthoformate (100 ml, 914 mmol). The reaction mixture was then vigorously stirred. After 5 days, additional trimethylorthoformate (50 ml, 457 mmol) was added. The reaction was stopped after 9 days (TLC-control: petroleum ether/Et20, 1:2), filtered over celite and washed with methanol. The solvent was removed in vacuo (20 mbar). The brown residue was transferred with CH2C12 (150 ml) into a separation funnel and washed with satd. NaHCO3 solution and brine (each 150 ml). The aqueous layers were extracted 3 times with CH2C12 (3x 150 ml). The combined organic layers were dried over Na2SO4, filtered and concentrated in vacuo (20 mbar) to afford diester I as a brownish oil (57.5 g, 88%).
Synthesis of intermediate II:
To a stirred suspension of diester 1(2.00 g, 10.1 mmol) in pH 7.00 phosphate buffer solution (103 ml, 0.07 M), PLE (8.00 mg, 216 units) was added. The pH was kept at 7 by adding continuously NaOH solution (1.0 M) via syringe pump. The reaction was stirred at 20 C until one equivalent of NaOH
(10 ml) was used (56.5 h, TLC-control: petroleum ether/Et20, 1:2). The reaction mixture was transferred into a separation funnel with ethyl acetate (100 ml). The layers were separated and the organic layer was extracted twice with pH 7.00 phosphate buffer solution (2x 60 ml). The combined aqu'ous layers were acidified to pH 2 with 1 M HCI solution and extracted four times with ethyl acetate (4x 150 m1). To separate the layers NaCI was added. The combined organic layers were dried over Na2SO4, filtered and concentrated in vacuo to afford the monoesterll as a yellowish oil (1.67 g, 90%). 96.0% ee7 (GC), 96.4%
ee. (rot.), [a]D21 zi (c = 0.195, Et0H), (Lit. + 15.8 (c = 0.2, Et0H), [Angew. Chem. mt. Ed. EngL, 1984, 23, 142]).
Synthesis of intermediate III:
A solution of monoester 11 (0.992 g, 5.38 mmol) in dry CH2Cl2 (18 ml) was treated with (C0C1)2 (0.7 ml, 8.15 mmol) and DMF (14 pl), stirred for h at r.t. and evaporated (rotavapor purged with argon). A solution of the residue in dry THF (20 ml) was added dropwise over a period of 20 minutes to a boiling suspension of 2-mercaptopyridine-1-oxide sodium salt (974.8 mg, 6.49 mmol), t-BuSH (3.1 ml, 27.5 mmol), and 4-DMAP (26.3 mg, 0.216 mmol) in dry THE (50 ml). The solution was stirred at reflux for 3h (TLC-control: p petroleum ether/Et20, 10:1). The reaction mixture was then cooled down to r,t. (room temperature) and transferred into a separation funnel with ethyl acetate (50 ml) and washed with water (100 ml). The aqueous layer was extracted twice with ethyl acetate (2x 100 ml). The combined organic layers were dried over Na2SO4, filtered and concentrated in vacuo (200 mbar). The crude product was purified by column chromatography (petroleum ether/Et20, 30:1 to 15:1) to afford methylester III as a yellowish oil (584.9 mg, 83%). + 78.23.
(c= 1.010, CHCI3).
Synthesis of intermediate IV:
To a stirred suspension of methylester III (5.19 g, 37.0 mmol) in pH 7.00 phosphate buffer solution (520 ml, 0.07 M), PLE (51.2 mg, 1382 units) was added. The pH was kept at 7 by adding NaOH solution (1.0 M) via syringe pump. The reaction was stirred at r.t. until one equivalent of NaOH (37 ml) was used (11 h, TLC-control: petroleum ether/Et20, 1:1). The reaction mixture was transferred into a separation funnel and washed twice with ethyl acetate (2x 300 ml). The layers were separated and the organic layers were extracted twice with pH 7.00 phosphate buffer solution (2x 300 ml). The combined aqueous layers were acidified to pH 2 with aqueous HCI (30 ml, 4 M) and extracted three times with ethyl acetate (3x 400 ml). The combined organic layers were dried over Na2SO4, filtered and concentrated in vacuo (100 mbar).
The crude product was filtered through a short plug of silica affording acid IV as a pale yellowish oil (3.92 g, 84%). 96.3% ee. (GC), 94.3% ee. (rot.), [a]D21+
89.12 (c = 6.730, Me0H), (Lit. + 94.5 (c = 7, Me0H), [Acta Chem. Scand., 1970, 24, 2693]).
Synthesis of intermediate V:
Acid IV (8.30 g, 65.7 mmol) was placed in a flask purged with argon and suspended in water (180 ml). The reaction mixture was cooled down to 0 C and NaHCO3 (16.6 g, 197 mmol) was added, followed by a solution of KI
(65.4 g, 394 mmol) and iodine (17.5 g, 68.9 mmol) in water (150 ml). The reaction was stirred at r.t. for 24 h and then extracted three times with CH2Cl2 (3x 60 ml). The combined organic layers were washed with a solution of Na2S203 (50 g) in water (250 ml). The aqueous layer was extracted twice with CH2Cl2 (2x 60 ml). The combined organic layers were protected from light, dried over Na2SO4, filtered and concentrated in vacuo (20 mbar) and quickly in high vacuo to afford iodolactone V as an off-white solid (15.79 g, 95%).
[ociD21+
35.96 (c = 0.565, CHCI3).
Synthesis of intermediate VI:
lodolactone V (15.73 g, 62.2 mmol) was dissolved in dry THF
(340 ml). Then DBU (14 ml, 93.3 mmol) was added and the mixture was refluxed for 20 h (TLC-control: petroleum ether/Et20, 1:1). The reaction mixture was cooled down to r.t., transferred with Et20 (200 ml) into a separation funnel and extracted with aqueous HCI (400 ml, 0.5 M) and brine (400 ml). The aqueous layers were extracted three times with Et20 (3x 200 m1). The combined organic layers were dried over Na2SO4, filtered and concentrated in vacuo (350 mbar). The crude product was purified by column chromatography (petroleum ether/CH2Cl2/Et20, 20:5:1 to 8:5:1) to afford lactone VI as a yellowish oil (7.28 g, 94%). [a]D21+ 187.31 (c = 1.080, CHCI3).
Synthesis of intermediate VII:
NaHCO3 (4.36 g, 51.8 mmol) was dried in high vacuum for 2 h.
Then, freshly distilled methanol (268 ml) was added followed by lactone VI
(6.38 g, 51.4 mmol). The reaction mixture was then stirred under argon for 12 h (TLC-control: petroleum ether/Et20, 1:1). The solvent was evaporated and the residue transferred into a separation funnel with CH2Cl2 (60 ml) and extracted with water (60 ml) and brine (60 ml). The aqueous layers were extracted twice with CH2Cl2 (2x 60 m1). The combined organic layers were dried over Na2SO4, filtered and concentrated in vacuo (50 mbar) to obtain the alcohol as a yellowish oil (7.77 g, 96%). To a solution of the alcohol in dry CH2Cl2 (150 ml), tert-butyldimethylsilyl chloride (14.93 g, 99 mmol) was added in small portions, followed by DBU (18.4 ml, 123.4 mmol). The reaction was stirred at r.t for 12 h (TLC-control: petroleum ether/Et20, 20:1) and then quenched with methanol (20 ml). The reaction mixture was transferred into a separation funnel with CH2Cl2 (100 ml), washed with satd. NaHCO3 solution (100 ml) and brine (100 ml). The aqueous layers were extracted twice with CH2Cl2 (2x 100m1). The combined organic layers were dried over Na2SO4, filtered and evaporated (200 mbar).
The crude product was purified by column chromatography (petroleum ether/Et20, 40:1 to 20:1) to afford silylether VII as a colourless oil (13.96 g, quantitative yield). [ociD21+ 1.970 =
( 1.045, CHCI3).

Synthesis of intermediate VIII:
A solution of silylether VII (1.21 g, 4.47 mmol) in CH2Cl2 (36 ml) was cooled to 10 C, then m-CPBA (1.92 g, 11.1 mmol) was added in one portion. The reaction mixture was stirred at 10 C for 15 h. Over a period of 2 hours the temperature was raised to r.t and the reaction stopped (TLC-control:
petroleum ether/Et20, 5:1). The mixture was diluted with CH2Cl2 (150 ml) and transferred into a separation funnel. The excess of m-CPBA was destroyed by washing twice with satd. Na2S203 solution (2x 150 ml). The organic layer was successively washed with satd. NaHCO3 solution (150 ml) and brine (150 ml).
The aqueous layers were extracted twice with CH2Cl2 (2x 100 ml). The combined organic layers were dried over Na2SO4, filtered and concentrated in vacuo. The crude product was purified by column chromatography (petroleum ether/Et20, 12:1 to 10:1) to obtain epoxide VIII as yellowish oil (1.001 g, 78%).
[a]D21- 25.60 (c = 0.985, CHCI3).
Synthesis of intermediate IX:
CuCN (635.4 mg, 7.09 mmol) was dried in high vacuo at 150 C
for 30 minutes, suspended in dry THF (10 ml) and cooled down to -78 C. MeLi (1.6 M in Et20, 8.90 ml, 14.2 mmol) was slowly added via syringe and the temperature was raised over a period of 30 minutes to -10 C. The mixture was again cooled down to -78 C followed by the addition of freshly distilled BF3 etherate (360 pl) in THE (2 ml). After stirring for 20 minutes, epoxide VIII
(408.0 mg, 1.42 mmol) in THE (10 ml) was added. The reaction was stopped after 5 h stirring at -78 C (TLC-control: petroleum ether/Et20, 3:1). The excess of MeLi was quenched with a mixture of methanol (4 ml) and triethylamine (4 ml). The mixture was transferred with Et20 (100 ml) into a separation funnel and extracted with 25% aq. NH3/satd. NH4CI (1:9) solution. The organic layer was then successively washed with brine (60 ml), 5% acetic acid (60 ml), satd.
NaHCO3 solution (60 ml) and brine (60 ml). The aqueous layers were extracted twice with Et20 (2x 100 m1). The combined organic layers were dried over Per/US2007/021541 Na2SO4, filtered and concentrated in vacuo (20 mbar). The crude product was purified by column chromatography (petroleum ether/Et20, 10:1 to 8:1) to afford GicNAc-mimic IX as a reddish oil (337.0 mg, 78%). [a]D21- 28.34 (c = 1.020, CHCI3).
Synthesis of intermediate X:
After a mixture of IX (347.5 mg, 1.15 mmol), ethyl 2,3,4-tri-O-benzyl-L-fucothiopyranoside (1111 g, 2.32 mmol), (Bu)4NBr (1.122 g, 348 mmol), 2,6-di-tert-butyl-4-methylpyridine (713.3 mg, 3.47 mmol), and powdered 4A molecular sieves (3 g) in CH2Cl2 (12 ml) and DMF (3 ml) was stirred at r.t.
under Ar for 4 h, CuBr2 (775.9 mg, 3.47 mmol) was added and the reaction mixture was stirred at r.t. for 20 h (TLC-control: toluene/petroleum ether/Et0Ac, 3:3:1). The reaction mixture was filtered over Celia and the filtrate was diluted with CH2Cl2 (20 m1). The organic layer was washed with saki NalIC03 solution and brine (each 40 ml) and the aqueous layers were extracted three times with CH2Cl2 (3 x 40 ml), The combined organic layers were dried with Na2B04, filtered and co-evaporated with toluene to dryness. The residue was purified by column chromatography (petroleum ether/Et20, 7:1 to 5:1) to yield compound X
as a yellowish oil (631.4 mg, 76%). fajo21- 40.66 (c = 0.790, CHCI3).
Synthesis of intermediate XI:
To a solution of disaccharide mimic X (139.5 mg, 0.194 mmol) in TI-IF (5 ml), TBAF (390 pi, 0.390 mmol) was added. After 26 h additional TBAF
(200 pi, 0.200 mmol) was added, and the solution was continued stirring. The reaction was stopped after 50 h and concentrated in vacuo (TLC-control:
petroleum ether/ethyl acetate, 5:1). The crude product was purified by column chromatography (petroleum ether/ethyl acetate, 3:1) to afford the unprotected disaccharide mimic XI as a white solid (95.7 mg, 81%). [a]D21- 43.03 (c = 1.090, CHCI3).
*Trademark Synthesis of intermediate XII:
Dry CH2Cl2 (16 ml) was added to a mixture of the thioglycoside (562.3 mg, 0/19 mmol), glycosyl acceptor XI (335.6 mg, 0.555 mmol) and activated 4A molecular sieves (4 g) under argon atmosphere. A suspension of DMTST (440.6 mg, 1.706 mmol) and activated 4A molecular sieves (2 g)ifl CH2Cl2 (8 ml) was prepared in a second flask. Both suspensions were stirred at room temperature for 4 h, before adding the DMIST suspension via syringe to the other suspension with some additional C1-12C12 (1 m1). The reaction was stopped after 63 h (TLC-control: petroleum ether/Et20, 1:1), and filtered through ce114, washing with CH2C12. The filtrate was successively washed with satd.
solution of NaHCO3 (40 ml) and water (100 m1). The aqueous layers were three times extracted with DCM (3 x 60 m1). The combined organic layers were dried with Na2804, filtered and concentrated in vacuo. The crude product was purified by repeated column chromatography (petroleum ether/Et20, 1:1) to afford tetrasaccharide XII as a white foam (484.9 mg, 66%). [4)21- 52.80 (c = 1.050, CHCI3).
Synthesis of product XIII:
A mixture of XII (132.5 mg, 0.100 mmol), Pd(OH)2/C (50 mg), dioxane (3 ml) and water (0.75 ml) was hydrogenated in a Parr-shaker under 4 bar at r.t After 20 h the mixture was filtered through Celite and set up with new Pd(OH)21C (50 mg) for another 26 h, after which TLC control indicated je completion of the reaction. The reaction mixture was filtered over Celite and evaporated to dryness. The residue was redissolved in methanol (4 ml) and sodium rnethanolate (0.150 mmol in 160 pi MeOH) was added. After stirring at r.t. for 16 h the reaction was quenched by addition of acetic acid (17 pl).
The mixture was concentrated in VaCUO and purified by preparative, reversed-phase HPLC to afford compound XIII as a white solid (57.1 mg, 78%). Ictie21¨ 85.02 (c = 0.570, Me0H).
*Trademark SYNTHESIS OF GIcNAc Mimics FROM CYCLOHEXENON (Fig. 2) Synthesis of intermediate XIV:
2-Cyclohexenone (9.8 ml, 101 mmol) was dissolved in CH2Cl2 (250 ml) in a light protected flask, then the solution was cooled to 0 C.
Bromine (5.4 ml, 105 rnmol) in CH2Cl2 (100 ml) was added via dropping funnel over 35 min. The clear yellow solution was stirred at 0 C for 2.5 h, then Et3N (23.1 ml, 166 mmol) In CH2Cl2 (20 ml) was added portion-wise via dropping funnel, causing a colour change from clear yellow to brown with precipitate. The mixture was stirred at room temperature for 2 h, then stopped. The reaction mixture was diluted with CH2Cl2 (50 ml) and washed twice with HCI 3% x 50 ml). The aqueous layers were extracted with CH2Cl2 (2 x 25 ml) and the combined organic layers were washed With a mixture of brine (80 ml) and water (100 ml). The layers were separated and the aqueous layer was extracted with CH2Cl2 (2 x 50 ml). The combined organic layers were concentrated in vacuo to afford a brown residue still dissolved in a few ml of CH2Cl2, and was then treated with activated charcoal and filtered through celite. The dear green mixture was concentrated to dryness. Recrystallization from hexane/Et0Ac (100 ml:few drops) gave offvvhite crystals. The crystals were dried in a desiccator for 12 h affording bromide XIV (11,0 g, 62.8 mmol, 62%). 1H-NMR
(CDCI3, 500.1 MHz): 8 = 2.07 (m, 2 H,11-5), 2.45 (m, 2 H, H-4), 2.63 (m, 2 Hs H-6) , 7.42 (t, 3./04.4 Hz, 1 H, 143).
Synthesis of intermediate XV:
(S)- a, a-diphenylprolinot (290 mg, 1.14 mmol) was dissolved in THF (20 ml) in a flame dried, light protected flask, then under stirring B(OMe)3 (153 pl, 1.37 mmol) was added via syringe to the solUtion, The mixture was stirred for 1 h at room temperature, before BH3-N1Al-diethylaniline (2.00 ml, 11.2 romol) was added and the resulting solution cooled to ¨10 C. A solution of *Trademark bromide XIV (2.00 g, 11.4 mmol) in THF (15 ml) was then added over 45 min.
The clear yellow mixture was stirred for 3 h at 0 C. After complete conversion of the ketone the reaction was quenched with HCI (1 rA, 20 ml). The resulting mixture was diluted with CH2Cl2 (40 ml) and water (50 ml). After separation the organic layer was washed with brine (20 ml) and both aqueous layers were extracted twice with CH2Cl2 (2 x 25 ml). The combined organic layers were dried with Na2SO4 and concentrated in vacuo. Chromatographic purification of the crude product (petroleum ether/Et20, 2:1 to 1.5:1) gave XV (1.89 g, 10.7 mmol, 93%) as a colourless oil and with an optical yield of 96% ee determined by optical rotation and derivatisation with (1R)-(¨)-MTPA-Cl. [a]D21= +83.0 (c = 1.01; CHCI3); 1H-NMR (CDCI3, 500.1 MHz): 8 = 1.59-1.66 (m, 1 H, H-5a), 1.69-1.77 (m, 1 H, H-5b), 1.86-1.97 (m, 2 H, H-6a, H-6b), 2.00-2.07 (m, 1 H, H-4a), 2.09-2.16 (m, 1 H, H-4b), 2.26 (m, 1 H, OH), 4.20 (m, 1 H, H-1), 6.19 (t, 3J = 4.0 Hz, 1 H, H-3).
Synthesis of intermediate XVI:
XV (7.33 g, 41.4 mmol) was dissolved in Et20 (43 ml) in a flame dried flask equipped with a dropping funnel. tert-BuLi (1.7 rA in pentane, 133 mmol) was dropwise added at ¨78 C over 1 h and 15 min. After complete addition, the clear yellowish mixture was stirred for further 1 h and 30 min at ¨
78 C and was then warmed up to ¨20 C over 3 hrs and 15 min. The reaction was quenched by addition of satd. solution of NaHCO3 (50 ml) and stirred for a further hour at room temperature. The reaction was diluted laV addition of water (20 ml) and Et20 (20 ml). The layers were separated and the aqueous layer extracted twice with Et20 (2 x 30 ml). The combined organic layers were dried with Na2SO4 and concentrated in vacuo (>200 mbar) to afford a yellow mixture (still presence of solvent) which was purified by column chromatography (petroleum ether/Et20, 2:1 to 1:1). The product was mostly concentrated in vacuo (>200 mbar), then the rest of the solvent was removed by distillation under argon with vigreux column to afford alcohol XVI (3.39 g, 34.6 mmol, 85%) as a clear brown oil. [a]D21= +117.7 (c = 0.95; CHCI3); 1H-NMR (CDCI3, 500.1 MHz): 8 = 1.53-1.64 (m, 3 H, H-5a, H-6a, OH), 1.68-1.77 (m, 1 H, H-5b), 1.87 (m, 1 H, H-6b), 1.92-2.06 (m, 2 H, H-4a, H-4b), 4.19 (s, 1 H, H-1), 5.74 (dd, 3J =
2.4, 10.0 Hz, 1 H, H-2), 5.82 (m, 1 H, H-3).
Synthesis of intermediate XVII:
Alcohol XVI (1.51 g, 15.3 mmol) was stirred in CH2Cl2 (35 ml) at room temperature. Trityl chloride (9.54 g, 34.2 mmol) was added to the mixture, then DBU (5.9 ml, 39.5 mmol) was added via syringe. The brown mixture was stirred for 45 h, then stopped. The reaction mixture was diluted with CH2Cl2 (50 ml) and washed with satd. solution of NaHCO3 (50 ml). The layers were separated and the aqueous layer was extracted twice with CH2Cl2 (2 x 25 ml). The combined organic layers were dried with Na2SO4 and concentrated to dryness. The resulting viscous brown oil was purified by column chromatography (petroleum ether/toluene, 11:1 to 4:1) affording tritylether XVII (3.72 g, 10.9 mmol, 71%) as a yellow solid. [a]D21= +74.6 (c = 1.15; CHCI3); 1H-NMR (CDCI3, 500.1 MHz): 8 = 1.31-1.41 (m, 3 H, H-5a, H-6), 1.68-1.76 (m, 1 H, H-5b), 1.80 (m, 1 H, H-4a), 1.98 (M, 1 H, H-4b), 4.06 (S, 1 H, H-1), 5.03 (M, 1 H, H-2), 5.61 (M, 1 H, H-3), 7.21-7.54 (M, 15 H, 3 C6115);
elemental analysis calcd (%) for C25H240 (340.46): C 88.20, H 7.10; found: C
88.01, H 7.29.
Synthesis of intermediate anti-XVIII:
Tritylether XVII (948 mg, 2.79 mmol) was dissolved under argon atmosphere in CH2Cl2 (30 ml) and NaHCO3 (281 mg, 3.34 mmol) was added.
The mixture was cooled to 0 C and under stirring m-chloroperbenzoic acid (70 %, 960 mg, 5.56 mmol) was added. After stirring for 1.5 h the reaction temperature was gradually raised to room temperature and the mixture was stirred for another 3.5 h. The reaction was diluted with CH2Cl2 (50 ml) and transferred to a separation funnel. The excess of m-chloroperbenzoic acid was destroyed by washing with satd. solution of Na2S203 (2 x 150 m1)., The organic layer was then successively washed with satd. Na2CO3 solution (150 ml) and brine (150 m1). The aqueous layers were each time extracted with CH2Cl2 (2 x 50 ml). The combined organic layers were dried with Na2SO4 and concentrated in vacuo. The crude product was purified by column chromatography (petroleum ether/Et0Ac, 20:1 to 15:1) affording epoxide anti-XVIII,(714 mg, 2.00 mmol, 72 %) as colourless solid. [U]D21 =
+26.6 (c = 0.67; CHCI3); 1H-NMR
(CDCI3, 500.1 MHz): 8 = 1.02-1.11 (m, 1 H, H-5a), 1.15-1.22 (m, 1 H, H-6a), 1.37-1.43 (m, 1 H, H-5b), 1.53 (m, 1 H, H-6b), 1.64-1.71 (M, 1 H, H-4a), 1.90 (m, 1 H, H-4b), 2.25 (m, 1 H, H-2). 2.97 (M, 1 H, H-3), 3.86 (M, 1 H, H-1), 7.23-7.53 (M, 15 H, 3 C6H5); elemental analysis calcd (%) for C25H2402 (356.46): C
84.24, H 6.79; found: C 83.86, H 6.85.
Synthesis of intermediate XIX:
Copper(I) iodide (499 mg, 2.62 mmol) was dried at high vacuo at 200 C for 30 minutes, then flushed with argon and suspended in dry diethylether (10 ml). After cooling to ¨ 20 C MeLi (1.6 rvi in ether, 3.26 ml, 5.22 mmol) was slowly added and the solution was stirred for 15 minutes. A solution of epoxide anti-XVIII (310 mg, 0.870 mmol) in diethylether (7 ml) was added to the cuprate. After stirring for 30 minutes at ¨20 C the reaction mixture was slowly brought to room temperature and stirred for one week. The reaction was diluted with tert-butyl methyl ether (10 ml) and quenched at 0 C with satd.
solution of NaHCO3 (10 ml). The reaction mixture was further diluted and extracted with tert-butyl methyl ether and satd. solution of NaHCO3 (each 20 ml). The aqueous layer was extracted twice with tert-butyl methyl ether (2 x ml). The combined organic layers were dried with Na2SO4 and concentrated.
The residue was purified by flash chromatography (petroleum ether/Et0Ac/Et3N, 13:1:0.07) to yield XIX (206 mg, 64%) as yellowish resin.
[ajDzi = (c =
0.52; CHCI3); 1H-NMR (CDCI3, 500.1 MHz): 5 = 0.78 (m, 1 H, H-5a), 0.94 (m, 1 H, H-4a), 1.00 (d, 3J6.4 Hz, 3 H, Cl-I3), 1.17 (m, 1 H, H-3), 1.32 (m, 1 H, H-6,), 1.40 (m, 1 H, H-5b), 1.46-1.49 (m, 2 H, H-4b, H-6b), 2.67 (s, 1 H, OH), 2.83 (ddd, 3J.4.1, 8.6, 11.1 Hz, 1 H, H-1), 3.32 (t, 3J.9.2 Hz, 1 H, H-2), 7.21-7.30, 7.49-7.50 (m, 15 H, 3 C6H5); elemental analysis calcd (%) for C26H2802 (372.51): C 83.83, H 7.58; found: C 83.51, H 7.56.
Synthesis of intermediate XX:
A solution of Br2 (43 I, 0.837 mmol) in CH2Cl2 (1 ml) was added dropwise at 0 C to a solution of ethyl 2,3,4-tri-O-benzyl-L-fucothiopyranoside (349 mg, 0.729 mmol) in CH2Cl2 (2 ml). After stirring for 50 min at 0 C, cyclohexene (100 I) was added and the solution stirred for another 20 min.
The mixture was dropwise added to a solution of XIX (208 mg, 0.558 mmol) and EtiNBr (154 mg, 0.733 mmol) in DMF/CH2Cl2 (10 ml, 1:1) which has been stirred with activated 3A molecular sieves (850 mg) for 2 h. The mixture was stirred for 14 h at room temperature. The reaction was quenched with pyridine (1 ml) and filtered over celite with addition of CH2Cl2 (20 ml). The solution was washed with brine (40 ml) and the aqueous layer was extracted with CH2Cl2 (3 x 30 ml). The combined organic phases were dried with Na2SO4, the solvent was removed azeotropic with toluene, and the residue was purified by flash chromatography (petroleum ether/toluene/ethyl acetate/Et3N, 20:5:1:0.26) to afford 254 mg (581)/0, 0.322 mmol) of XX as colorless foam. [a]D21= -36.4 (c = 0.51; CHCI3); 1H-NMR (CDCI3, 500.1 MHz): 6 = 0.81 (d, 3J-6.5 Hz, 3 H, Fuc H-6), 1.05 (m, 1 H, H-6,), 1.18 (d, 3J7.6 Hz, 3 H, CH3), 1.15-1.28 (m, 2 H, H-4,, H-5,), 1.34 (m, 1 H, H-6b), 1.75 (m, 1 H, H-4b), 1.85-1.90 (m, 2 H, H-3, H-5b), 2.91 (m, 1 H, H-2), 3.52 (m, 1 H, Fuc H-4), 3.64 (m, 1 H, Fuc H-5), 3.76 (dd, 3J=2.7, 10.1 Hz, 1 H, Fuc H-3), 3.81 (m, 1 H, H-1), 3.88 (dd, 3J = 3.6, 10.1 Hz, 1 H, Fuc H-2), 4.54 (m, 1 H, CH2Ph), 4.61 (d, 1 H, Fuc H-1), 4.61, 4.64, 4.65, 4.77, 4.92 (5 m, 5 H, 3 CH2Ph), 7.17-7.34, 7.48-7.50 (m, 30 H, 6 C6H5).

PCT/US2007/021.541 Synthesis of intermediate XXI:
To a stirred solution of tritylether XX (241 mg, 0.305 mmol) in CH2Cl2 (4 ml), ZnBr2 (208 mg, 0.924 mmol) and triethylsilane (55 tl, 0.344 mmol) was added. The reaction was quenched after 8 h by adding 100 ill water. CH2Cl2 (10 ml) was added and the reaction mixture extracted with said.
solution of NaHCO3 (30 ml). After separation the aqueous layer was extracted twice with DCM (2 x 20 m1). The combined organic layers were washed with satd. solution of NaHCO3 (50 ml) and the aqueous layer was extracted twice with DCM (2 x 50 ml). The combined organic layers were dried with Na2SO4 and concentrated in vacuo. Chromatographic purification of the crude product (petroleum etherftoluene/ethyl acetate, 5:5:1) gave 140 mg (84 %, 0.256 mmol) of XXI as yellowish solid. [ct]D21.-35.0 (c = 0A5; CHCI3);1H-NMR (CDCI3, 500.1 MHz): 6 = 0.98 (m, I H, H-43), 1.08 (d,3J.6.4 Hz, 3H, CH3), 1.16 (d, 3J.6.5 Hz, 3 H, RIC H-6), 1.22-1.30 (rn, 2 H, H-5,, H-6,), 1.51 (m, 1 H, H-3), 1.61-1.67 (m, 2 H, H-4b, H-5b), 2.00(m, 1 H, H-6b), 2.87 (t, 3J= 9.3 Hz, I H, 1-1-2), 3.37 (m, 1 H, H-1), 3/0 (m, I H, Fuc H-4), 3.97 (dd, 3./.2..7, 102 Hz, 1 H, Fuc H-3), 4.10-4.14 (m, 2 Fuc 1-1-2, Fuc H-5), 4.65, 4.70, 4.76, 4.77, 4.86, 4.99 (6 m, 6 H, 3 CH2Ph), 5.00 (d, 1 H, Fuc H-1), 7.25-7.39 (m, 15 H, 3 C51-15);
elemental analysis calcd (%) for C34H4206 (546.69): C 74.70, H 7.74; found: C
74.68, H 7.80.
Synthesis of intermediate XXII:
Dry CH2Cl2 (8 ml) was added to a mixture of the thioglycoside (254 mg, 0.325 mmol), the glycosyl acceptor XXI (137 mg, 0.251 MOO and activated 4A molecular sieves (2 g) under argon atmosphere. A suspension of DMTST (206 mg, 0.798 mmol) and activated 4A molecular sieves (1 g) in CH2Cl2 was prepared in a second flask. Both suspensions were stirred at room temperature for 4 h, before adding the DMTST suspension via syringe to the other suspension. The reaction was stopped after 43 hand filtered through celite, washing with CH2Cl2. The filtrate was successively washed with satd.
*Trademark solution of NaHCO3 (20 ml) and water (60 ml). The aqueous layers were each time extracted with DCM (3 x 30 ml). The combined organic layers were dried with Na2SO4 and concentrated in vacuo. The crude product was purified by column chromatography (petroleum ether/toluene/ethyl acetate, 7:7:1 to 5:5:1) to afford 187 mg (59%, 0.148 mmol) of XXII as colourless foam. [4321 -51.0 (c = 0.51; CHCI3); 1H-NMR (CDCI3, 500 1 MHz): 8 = 0A5-1A6 (m, 19 H, CyCH2, MeCy), 1.04 (d, 3.1.6.3 Hz, 3 H, CH3), 1.44 (d, 3J.6.4 Hz, 3k, Fix H-6), 1.86 (m, 1 H, MeCy), 3.21 (t, 3.1.9.1 Hz, 11, 11-2), 3.48 (m, 1 H, H-1), 3.51 (s. 1 H, Fuc H-4), 3.82 (dd, 3J. 3.3, 9.9 Hz, 1 H, Gal H-3), 3.91 (m, 1 11, Gal H-5), 4.02 (dd, 3,1.3.3, 10.3 Hz, 1 H, Fuc 1-1-2), 4.05 (dd, 3,1. 2.3, 10.3 Hz, 1 H, Fug H-3), 4.12 (dd, 3J.4.6, 7.9 Hz, 1 1-1, Lec H-2), 4.24 (dd, 3J7.2 Hz,2.1.11.4 Hz, 1 H, Gal H-6.), 426(m, I H, CH2Ph), 4.38 (dd,3J.5.7 Hz,2.1.11.4 Hz, 1 H, Gal H-6b), 4.51 (m, 1 H, CH2Ph), 434d, 341,82 Hz, 1H, Gal H-1), 4.63, 4.67, 4.74, 4.77 (4 m, 4 H, 2 CH2Ph), 4.88 (m, 1 II, Ric H-5), 5.05 (m, 1 H, CH2Ph), 5.06 (d, 3J.3.5 Hz, 1 H, Fuc H-1), 5.11 (m, I H, CH2Ph), 5.60 (m,1 H, Gal H-2), 5.84 (m, 1 H. Gal H-4), 7.17-7.34, 7.42-7A6, 7.52-7.58, 8.03-8.12 (m, 35 H, 7 C5115); elemental analysis calcd (%) for C77H8.40i6 (1265.48): C 73.08, H
6.69;
found: C 7316, H 6.76.
Synthesis of product XXIII:
Pd/C (50 mg, 10 % Pd) was suspended under argon atmosphere in ethanol (3 ml) with a catalytic amount of acetic acid. Compound XXII (101 mg, 79.8 1.tmo1) was added and the resulting mixture was hydrogenated under 70 psi at room temperature. After 1 day another 50 mg of P&G were added and hydrogenation was continued for another 5 days. The reaction was quenched with CH2Cl2 and filtered on cella washing with methanol. The filtrate was concentrated under vacuum, redissolved in methanol/water (3:1, 4 ml) and lithium hydroxide (100 mg, 4.18 mmol) was added. After 2 days stirring the mixture was neutralized with Dowex 50x8 (HI filtered through a Dowex 50 ion exchanger column (Nat form) and concentrated in vacuo. The residue was *Trademark WO 2008/060378 Per/UW.007/021541 purified by column chromatography (CH2C12/Methanolfwater, 5:1:0.1 to 5:2.5:0.25), followed by SephadetG15 column and lyophilization from dioxane to give 36.5 mg (74 %, 594 mmol) of XXIII as colourless foam. [O]e = 44.8 (c =032, Me0H); 1H-NMR (Me0D, 500.1 MHz): 8 = 0.87-1.00 (m, 2 H, CyCH2, MeCy), 1.04-1.38 (m, 6H, CyCH2, MeCy), 1.13 (d, 34.6.3 Hz, 3 H, CH3), 1.20 (d, 3,1.6.5 Hz, 3 H, FucH-6), 1.55-1.74 (m, 10 H, CyCH2, MeCy), 1.92 (m, 1 H), 2.13 (m, 1 H, MeCy), 3.20(t 349.3 Hz, 'I H, H-2), 3.24 (dd, 34,2.8, 9.3 Hz, 1 H, Gal H-3), 3.42 (m, 1 H, Gal H-5), 3.62-168 (m, 3 H, Gal H-2, Gal H-6a, H-1), 3.70-3.75 (m, 3 H, Fuc 142, FucH-4, Gal H-6b), 3.85 (dd, 3413, 10.3 Hz, 1 H, Fuc H-3), 3.88 (m, 1 H, Gall-1-4) 4.07 (dd,3J.3.1, 9.311z, 1 H, Lac H-2), 4.29 (d, 34 7.8 Hz, 1 H, Gal H-1), 4.89 (m, 1 H, Fuc H-5), 5.00 (d, 3../.3.9 Hz, 1 H, FucH-1); elemental analysis calcd (%) for C28H47Na013. 1 H20 (614.65+18.02):
C 5316, H 7.81; found: C 53.22, H 7.91.

((1R2R,3S)-24(6.0Eort-a-L-GALAcToPYRANosY1-)0x1-3-ETHYL.-cYcL0i-mx-1-yL) 2-0-BENzoN1-3-04(1S)-1-CARBOXY-2-CYCLOHEXYL-ETHYLI-0-D-GALACTOPYRANOSIDE (AVIV; FIG. 3) General procedure A for nucleophilic openino of epoxide A-I with cuprate reagents;
CuCN (3.81 mmol) was dried in yaw at 150 C for 30 min, suspended in dry THF (10 mL) and cooled to -78 C. A solution of the appropriate organo lithium compound (7,63 mmol) was slowly added via syringe and the temperature was raised over a period of 30 min to -20 C and the mixture stirred at this temperature for 10 min. The mixture was cooled to -78 C followed by the addition of freshly distilled BF3 etherate (1.53 mmol) in THF (2 rnL). After stirring for 20 min, epoxide A-I (0.761 mmol) dissolved in THF (8 was added. The reaction was slowly warmed to -50 C over 5 h and then stirred at this temperature for 24 h. After slowly warming the reaction to -30 C over another 21 h the reaction was quenched with a 25% aq. NH3/satd.
*Trademark NI-LICI (1:9,20 mL) solution. The mbdure was transferred with Et20 (30 mL) Into, a separation funnel and extracted with additional 25% aq. NH3/satd.

(1:9, 30 mL) solution. The layers were separated and the organic layer was washed with brine (50 at). The aqueous layers were extracted with Et20 (2 x 30 mL). The combined organic layers were dried over Na2SO4, filtered and concentrated in vacua The crude product was purified by column chromatography (petroleum ether/Et20, 20:1 to 13:1, + 1% Et3N) to afford the corresponding GicNAc mimic, General procedure B for ct-fucosylation and detritvlation.
A solution of Br2 (0.837 mmol) in CH2C12 (1 mi.) was added dropwise at 0 C to a solution of ethyl 2,3,441-0-benzy1-1-thio-L-fucopyranoside 0.729 mmol) in CH2C12 (2 mL). After stirring for 50 min at 0 C, cyclohexene (100 was added and the solution stirred for another 20 min.
The mixture was added dropwise to a solution of the appropriate GIcIVAc MiMiC
(0.558 mmol) and Et4NBr (0.733 mmol) in DMF/CH2Cl2 (10 mL, 1:1), which has been stirred with activated 3A molecular sieves (850 mg) for 2 h. The mixture was stirred for 14h at r.t. The reaction was quenched with pyridine (1 mL) and filtered over celite with addition of CH2Cl2 (20 mL). The solution was washed with brine (40 mL) and the aqueous layer was extracted with CH2Cl2 (3 x 30 mL). The combined organic phases were dried with Na2SO4, filtered and the solvents were removed azeotropically with toluene. The residue was purified by flash chromatography (petroleum ether/diethyl ether, 12:1 to 7:1, + 1%
Et3N) to afford the fucosylated tritylether. To a stirred solution of the tritylether (0.305 mmol) in CH2Cl2 (4 mL), ZnBr2 (0.924 mmol) and triethylsilane (0.344 mmol) were added. The reaction was quenched after 8 h by adding water (100 pL).
CH2Cl2 (10 mL) was added and the reaction mixture extracted with satd.
aqueous NaHCO3 (30 mL). The aqueous layer was extracted with DCM (2 x 20 mL). The combined organic layers were washed with satd. aqueous NaHCO3 (50 mL) and the aqueous layer was extracted wfth DCM (2 x 50 mt.). The *Trademark combined organic layers were dried with Na2SO4, filtered and concentrated in vacua Chromatographic purification of the crude product (petroleum ether/toluene/ethyl acetate, 77:1 to 4:4:1) afforded the corresponding disaccharide mimic.
General procedure C for DMTST promoted cdcosviations.
A solution of the thioglycoside A-M(0.292 rnmol) and the appropriate glycosyl acceptor (0.225 mmol) in dry CH2Cl2 (8 mL) was added via syringe to activated 3A molecular sieves (2 g) under argon. A suspension of dimethyl(methylthio)sulfonium triflate (DMTST) (0.685 mmol) and activated 3A
molecular sieves (1 g) in CH2Cl2 (4 mL) was prepared in a second flask. Both suspensions were stirred at r.t. for 4 h, then the DMTST suspension was added via syringe to the other suspension with some additional CH2Cl2 (2 ml). The reaction was stopped after 2 d, filtered through celite and the celite washed with CH2Cl2 (10 mL). The filtrate was successively washed with satd. aqueous NaHCO3 (25 mL) and water (40 mL). The aqueous layers were extracted with CH2Cl2 (3 x 25 mL). The combined organic layers were dried with Na2SO4, filtered and concentrated in vacua. The crude product was purified by column chromatography (petroleum ether/toluene/ethyl acetate, 10:10:1 to 5:5:1) to afford the corresponding tetrasaccharide mimic as a colorless foam.
General Procedure D for deorotection with Pd(OH)2/C and sodium methoxide.
Pd(OH)2/C (50 mg, 10% Pd) was suspended under argon in dioxane/H20 (4:1, 3.75 mL). The appropriate protected compound (77.7 limo') was added and the resulting mixture was hydrogenated under 70 psi at r.t.
After 24 h the mixture was filtered thmugh celite and reacted with!fresh Pd(OH)2/C (50 mg) for additional 48 h, until TLC control indicated completion of 4( =
the reaction. The reaction mixture was filtered through celite and evaporated to dryness. The residue was redissolved in methanol (5 mL) and sobium methoxide (0.194 mmol in 190 pl Me0H) was added. After stirring at r.t. for 16 h the reaction was quenched by addition of acetic acid (22 pL). The mixture was concentrated in vacuo and purified by preparative, reversed-phase HPLC
to afford the corresponding antagonists as colorless solids.
(1R,2R,3R)-3-Ethenv1-1-0-triphenvImethyl-cyclohexane-1,2-diol (A-II).
A vinyl lithium solution was generated in situ by treating a solution of tetravinyl tin (409 pL, 2.25 mmol) in THF (3 mL) with nBuLi (2.5 M in hexane, 3.35 mL, 8.38 mmol) during 30 min at 0 C. CuCN (373 mg, 4.16 mmol) in THF
(8 mL) was treated with the vinyl lithium solution and BF3 etherate (209 pL, 1.66 mmol) in THF (1.5 mL) according to general procedure A. Epoxide A-I (296 mg, 0.830 mmol) in THE (8 mL) was slowly added and the reaction slowly warmed to -30 C (-78 C: 15 min; -78 C to -50 C: 1.5 h; -50 : 13 h; -50 C to -30 C: 1.5 h; -30 C: 24 h). Work-up and purification according to general procedure A yielded A-II (258 mg, 81%) as a yellowish resin.
[cx1D21 _33.7 (c 0.53, CHCI3); 1H-NMR (CDCI3, 500.1 MHz) 5:
0.84 (m, 1 H, H-5.), 1.15 (m, 1 H, H-4.), 1.32 (m, 1 H, H-6.), 1.43-1.55 (m, 3 H, H-5b, H-6b, H-4b), 1.81 (m, 1 H, H-3), 2.66 (s, 1 H, OH), 2.91 (ddli, 3J= 3.9, 8.6, 11.3 Hz, 1 H, H-1), 3.51 (t, 3J= 9.3 Hz, 1 H, H-2), 5.02 (A of ABX, 3JA,x .10.4 Hz, 2JA,B= 1.7 Hz, 3JA,3. 0.7 Hz, 1 H, vinyl HA), 5.04 (B of ABX, 3JB,x = 17.2 Hz, 2JA,B= 1.7 Hz, 343. 1.1 Hz, 1 H, vinyl HB), 5.83 (X of ABX, 3JA,x= 10.4 Hz, 3.-/B,x= 17.2 Hz, 3Jx,3= 7.6 Hz, 1 H, vinyl Hx), 7.21-7.31, 7.48-7.50 (2 m, 15 H, 3 C6H5); 13C-NMR (CDCI3, 125.8 MHz) 8: 23.18 (C-5), 30.39 (C-4), 32.21 (C-6), 47.30 (C-3), 76.74 (C-2), 78.53 (C-1), 114.77 (vinyl C), 127.11, 127.77, 128.75, 145.07 (18 C, 3 C6H5), 140.57 (vinyl C); IR (film on NaCI) v: 3577 (m, OH), 3059 (m), 2932 (vs), 2860 (s), 1641 (vw), 1597 (vw), 1489 (s), 1448 (s), 1278 (m), 1225 (m), 1152 (w), 1064 (vs), 991 (s), 915 (m) cm-1; elemental analysis calcd (%) for C27H2802 (384.51): C 84.34, H 7.34; found: C 84.15, H 7.33.
f(1R,2R,3R)-3-Etheny1-1-hydroxv-cyclohex-2-yll 2,3,4-tris-0-benzv1-6-deoxv-a-L-galactopyranoside (A-IV).
According to general procedure B, A-III (205 mg, 0.428 mmol) in CH2Cl2 (1.5 mL) was treated with a solution of Br2 (25.5 pL, 0.496 mmol) in CH2Cl2 (1 mL) for 40 min at 0 C. After destroying the excess of bromine, the fucosyl bromide solution was added to a solution of A-II (126 mg, 0.329 mmol) and Et4NBr (90.8 mg, 0.432 mmol) in DMF/CH2Cl2 (6 mL, 1:1), which has been stirred with activated 3A molecular sieves (500 mg) for 4 h. The reaction was stirred for 67 h at r.t. and then quenched with pyridine (1 mL). Work-up and purification according to general procedure B yielded the tritylether (213 mg).
To a stirred solution of the tritylether in CH2Cl2 (4 mL), ZnBr2 (179 mg, 0.793 mmol) and triethylsilane (63 pL, 0.397 mmol) were added. The reaction was quenched after 2 h by adding H20 (100 pL). Work-up and purification according to general procedure B yielded A-IV (110 mg, 60% over two steps) as a colorless solid.
[a]c21 = -22.1 (c = 0.52, CHCI3); 1H-NMR (CDCI3, 500.1 MHz) 8:
1.15 (d, 3.-/F6,F5 = 6.5 Hz, 3 H, Fuc H-6), 1.17 (m, 1 H, H-4a), 1.26-1.30 (m, 2 H, H-5a, H-6a), 1.72 (m, 1 H, H-5b), 1.78 (m, 1 H, H-4b), 2.02 (m, 1 H, H-6b), 2.13 (m, 1 H, H-3), 3.04 (t, 3J= 9.5 Hz, 1 H, H-2), 3.45 (m, 1 H, H-1), 3.69 (m, 1 H, Fuc H-4), 3.98 (dd, 3.-/F3,F4 = 2.6 Hz, 3JF2,F3 = 10.1 Hz, 1 H, Fuc H-3), 4.10 (dd, 3µk1,F2 = 3.6 Hz, 3JF2,F3 = 10.1 Hz, 1 H, Fuc H-2), 4.12 (m, 1 H, Fuc H-5), 4.65, 4.70, 4.76, 4.78, (4 m, 4 H, 2 CH2Ph), 4.85 (m, 2 H, CH2Ph, vinyl H), 4.98 (m, H, vinyl H), 4.99 (m, 1 H, CH2Ph), 5.03 (d, 3JF1,F2 = 3.6 Hz, 1 H, Fuc H-1), 6.25 (m, 1 H, vinyl H), 7.27-7.40 (m, 15 H, 3 C6I-15); 13C-NMR (CDCI3, 125.8 MHz) 8:

16.55 (Fuc C-6), 22.81 (C-5), 29.67 (C-4), 32.39 (C-6), 44.33 (C-3), 67.56 (Fuc C-5), 72.97, 73.01 (CH2Ph, C-1), 73.38, 74.85(2 CH2Ph), 76.41 (Fuc C-2), 77.54 (Fuc C-4), 78.86 (Fuc C-3), 90.26 (C-2), 97.98 (Fuc C-1), 113.46 (vinyl C), 127.43, 127.48, 127.53, 127.63, 127.82, 128.23, 128.36 (18 C, 3 C6H5), 140.43 (vinyl C), IR (KBr) v: 3429 (s, OH), 3065 (w), 3031 (w), 2932 (s), 2866 (s), 1636 (vw), 1497 (w), 1454 (m), 1348 (m), 1308 (w), 1246 (vw), 1212 (w), 1161 (s), 1138 (s), 1101 (vs), 1064 (vs), 1027 (vs), 953 (m), 911 (w) cm-1;
elemental analysis calcd (%) for C35H4206 (558.70): C 75.24, H 7.58; found: C
74.91, H 7.55.

WO 2008/060378 PCT/1jS2007/021541 1t1g2R.3S)-3-Ettyl-1.twdroxy-evclohex-2-vil 2.3.4-tris-O-benzv1-6-deoxv-a-L-cialactopyranoside (A-V.
A solution of A-IV (90.0 mg, 0.161 mmol) in TI-IF (4 mL) was added to Pd/C (45.2 mg, 10% Pd) under argon. The mixture was hydrogenated under atmospheric pressure at r.t. After 30 min the reaction was filtered through celite, concentrated under reduced pressure and purified by column chromatography (toluene/petroleum ether/ethyl acetate, 7:7:1 to 5:5:1) to yield A-V (69.8 mg, 77%) as a colorless solid.
tai021 = -37.2 (c = 0.50, CHCI3); 1H-NMR (CDCI3, 500.1 MHz) 8:
0.78 (t, 3J = 7.5 Hz, 3 H, CH2CH3), 0-83 (M, H, H-4a), 1.06-126 (m, 3 H, CH2CH3, H-5a, H-6a), 1.16 (d, 345,F6 = 6.5 Hz, 3H, Fuc H-6), 1.30 (m, 1 H. 1-1-3), 1.67 (m, 1 H, H-5b), 1.79 (in, 1 H, H-4b), 1.99-2.074m, 2 H, H-6b, CH2CH3), 2.96 (dd, 3J = 8.6, 10.2 Hz, 1 H, H-2), 3.38 (ddd, 3.1= 4.8, 8.5, 10.6 Hz, 1 H, H-1), 3.70 (m, 1 11, Fuc I-I-4), 3.98 (dd, 3JF3,F4= 2.7 Hz, 343,F2= 10.2 Hz, 1 H, Fuc H-5), 4.10-4.14 (m, 2 H, Fuc 11-2, Fuc 11-5), 4.66, 4/0, 4.77, 4.80, 4.84(5 in, 5 H, CH2Ph), 4.89-5.00 (m, 2 H, Fuc H-1, CH2Ph), 7.27-7.40 (m, 15 H, 3 C6H5);
13C-NMR (CDCI3, 125.8 MHz) 6: 10.99 (CH2CH3), 16.60 (Fuc C-6), 23.09 (C-5), 24.17 (CH2CH3), 29.50 (C-4), 32.60 (C-6), 42.64 (C-3), 67.48 (Fuc C-5), 72.83, 73.13, 73A7 (C-1, 2 CH2Ph), 74.84 (CH2Ph), 76.32 (Fuc C-2), 77.37 (Fuc C-4), 78.86 (Fuc C-3), 91.07 (C-2), 98.31 (Fuc C-1), 127.40, 127.46, 127.50, 127.64, 127.80, 12821, 128.33, 128.39, 138.31, 138.39, 13870(18 C, 3 CeHs); HR-MS
(ESI) m/z: caicd for C35H44Na08 [114+Nar: 583.3030; found: 583.3018 (21 PPm).
1(1R.2R.3 SI-242.3.4-tris-0-benzyl-6-deqxv-a-Lialactopyrariosypoxyl-3-ethvl-cyclohex-1-y1) 2,4,6-tri-O-benzoy1-3-Q-1(1S)-1-berizyloxycarbonvi-2-cvd0hexvl-ethvII-B-o-9alactoovranoside (A-VII), According to general procedure C, thioglycoside A-VI (112 mg, 0.144 mmol) and glycosyl acceptor A-V (61.6 mg, 0.110 mmol) in dry CI-12C12 (4 mL) were added via syringe to activated 3A molecular sieves (1 g). A
suspension of DMTST (87.0 mg, 0.337 mmol) and activated 3A molecular sieves (500 mg) in CH2Cl2 (2 mL) was prepared in a second flask. Both *Trademark suspensions were stirred at r.t. for 4 h, then the DMTST suspension was added via syringe to the other suspension with some additional CH2Cl2 (1 mL). The reaction was stopped after 49.5 h and work-up and purification according to general procedure C afforded A-VI! (110 mg, 78%) as a colorless foam.
[a]D21 = -51.5 (c = 0.42, CHCI3); 1H-NMR (CDCI3, 500.1 MHz) E:
0.45-1.61 (m, 20 H, CyCH2, EtCy), 0.75 (t, 3J= 7.3 Hz, 3 H, CH2CH3), 1.41 (d, 3JF5,F6 = 6.4 Hz, 3 H, Fuc H-6), 1.84 (m, 1 H, H-6b), 1.92 (m, 1 H, CH2CH3), 3.31 (t, 3J = 8.7 Hz, 1 H, H-2), 3.49-3.52 (m, 2 H, H-1, Fuc H-4), 3.82 (dd, 3JG3,34 = 3.2 Hz, 3J32,33 = 9.8 Hz, 1 H, Gal H-3), 3.92 (m, 1 H, Gal H-5), 3.99-4.05 (m, 2 H, Fuc H-2, Fuc H-3), 4.12 (dd, 3J = 4.6, 7.9 Hz, 1 H, Lac H-2), 4.25 (dd, 3JG5,G6a = 7.2 Hz,./
3¨G6a,G6b = 11.4 Hz, 1 H, Gal H-6a), 4.28 (m, 1 H, CH2Ph), 4.39 (dd,./
3¨G5,G6b = 5.7 Hz, 3.-/36a,36b = 11.4 Hz, 1 H, Gal H-6b), 4.51-4.55 (m, 2 H, CH2Ph, Gal H-1), 4.63, 4.65, 4.75, 4.78 (4 m, 4 H, CH2Ph), 4.81 (m, 1 H, Fuc H-5), 4.98 (d, 3JF1,F2 = 2.8 Hz, 1 H, Fuc H-1), 5.04, 5.11 (2 m, 2 H, CH2Ph), 5.60 (m, 1 H, Gal H-2), 5.84 (m, 1 H, Gal H-4), 7.17-7.33, 7.42-7.46, 7.52-7.58, 8.04-8.12 (4 m, 35 H, 7 C6I-15); 13C-NMR (CDCI3, 125.8 MHz) 8: 10.94 (CH2CH3), 16.82 (Fuc C-6), 23.18 (CH2CH3), 22.11, 25.45, 25.71, 26.07, 27.89, 30.41, 32.60, 33.19, 33.40, 40.49 (10 C, EtCy, CyCH2), 44.71 (C-3), 62.50 (Gal C-6), 66.35 (Fuc C-5), 66.64 (CH2Ph), 70.17 (Gal C-4), 71.40 (Gal C-5), 72.07 (CH2Ph), 72.17 (Gal C-2), 74.29, 74.91 (2 CH2Ph), 76.42 (Fuc C-2), 78.06 (Gal C-3), 78.38 (Lac 0-2), 79.22, 79.27 (Fuc 0-4, C-2), 79.77 (Fuc C-3), 80.95 (C-1), 97.96 (Fuc C-1), 100.05 (Gal C-1), 126.94, 127.06, 127.21, 127.39, 127.77, 128.05, 128.10, 128.38, 128.44, 128.50, 128.54, 129.66, 129.93, 133.03, 133.17, 133.27, 135.40, 138.64, 139.01, 139.17 (42 C, 7 C6H5), 164.58, 166.11, 166.22, 172.48(4 C=0); elemental analysis calcd (%) for C781186016 (1279.51) + 1/2 H20: C 72.20, H 6.84; found:

C 72.37, H 6.82; HR-MS (ESI) m/z: calcd for C781-156Na016 [M+Nar: 1301.5808;
found: 1301.5855 (3.6 ppm).

ill R.213,3S)-24(6-deoxv-a.-L-aalactooyranosyl)oxy1-3-ethyl-cyclohex-1-v11 2-0-benzov1-3-04(1S)-1-carboxv-2-cyclohexvi-ethv11-0-o-galactopyranosicle Fig. 3).
A-V11 (382 mg, 29.9 pmol) was hydrogenated with Ftl(OH)2/C (50 mg, 10% Pd) in dioxane/H20 (4:1, 3.75 mL) according to general procedure D.
=4*
After 24 lithe reaction mixture was filtered through celite and evaporated to dryness. The residue was redissolved in methanol (5 mL) and sodium methoxide (74.6 prnol in 73 pl Me0H) was added. After stirring at r.t. for 16 h the reaction was quenched by addition of acetic acid (8.514 The mixture was concentrated in yam) and purified by preparative, reversed-phase HPLC to afford AVM (16.3 mg, 77%) as a colorless solid.
[0.1D21 = -89.3 (c = 0.47, Me0H); 1H-NMR (Me0D, 500.1 MHz) 8:
0.55-1.69 (m, 20 H, CyCH2, EtCy), 0.83 (t, 3.1= 7.3 Hz, 3 H, CH2CH3), 1.32 (d, 3J = 6.6 Hz, 3 H, Fuc H-6), 1.90(m, I H, CH2C113), 1.99(m, 1 H, H-66), 3.24t, 3,1= 8.9 Hz, 1 H, H-2), 3.57 (m, 1 H, Gal H-5,3.62 (m,1 H, H-1), 3.67 (dd, 343,G4 = 3.0 Hz,3JG2,q3= 9,8 Hz, 1 H, Gal H-3), 3.70-3.75 (m, 3 H, Gal H-8a, Fuc H-2, Fuc H-4), 3.79 (dd, 345,G6b = 6.9 Hz,2468,93b = 11.3 Hz, 1 H, Gal H-6b), 3.86 (dd, 3JF3,F4 = 3.3 Hz,3JF2,r3= 10.3 Hz, 1 Fuc H-3), 3.97 (m, 1 H, Gal H-4), 4.07 (dd, 3J = 3.0, 9.8 Hz, 1 H, Lao 11-2), 4.67 (d. 341,G2 = 8.1 Hz, H, Gal H-1), 4.90 (m, 1 H, Fuc 11-5), 4.91 (m, 1 H, RIC H-1), 5.43 (dd, 34i.q2 = 8.3 Hz, 3-Jo2,q3= 9.4 Hz, 1 H, Gal 11-2), 7.49-7.52, 7.61-7.64,8.08-8.09 (3 m, 5 H, C6H5);13C-NMR (Me0D, 125.8 MHz) 8: 11.12 (CH2CH3), 16.72 (Fuc C-6), 23.39, 24.59, 26.54, 26.72, 27.27, 29.47, 31.86, 33.14, 34.20, 35.06, 4276(11 C, EtCy, CH2Cy), 45.96 (C-3), 62.68 (Gal C-6), 67.77 (Fuc C-5), 67.83 (Gal C-4), 70.30 (Fuc C-2), 71.38 (Fuc C-3), 73.12 (Gal C-2), 73.92 (Fuc C-4), 75.90 (Gal C-5), 77.94 (Lac C-2), 80.77 (C-1), 81.11 (C-2), 83.55 (Gal C-3), 100.20 (Fuc C-1), 100.52 (Gal C-1), 129.67, 130.84,131.63, 134,37 (6 C, C6H5), 166.79 (C=0), 178.76 (CO21); HR-MS (ESI) m/z: calcd for C36H54N3014 [M+Nar: 733.3406; found: 733,3409 (0.4 ppm).
*Trademark {(1 R,2R,3R)-3-CYCLOPROPYL-2-[(6-DEOXY-a-L-GALACTOPYRANOSYL)OXY]-CYCLOHEX-1-YLI 2-0-BENZ0YL-3-0-[(1 -CARBOXY-2-CYCLOHEXYL-ETHYL]-13-D-GALACTOPYRANOSIDE (B-IV; FIG. 4) (1R,2R,3R)-3-Cyclopropv1-1-0-triphenylmethvl-cyclohexane-1,2-diol (B-I).
A cPrLi solution was generated in situ by treating a solution of bromocyclopropane (370 pL, 4.63 mmol) in THE (4 mL) with tBuLi (1.7 M in pentane, 5.45 mL, 9.27 mmol) during 80 min at -78 C. CuCN (210 mg, 2.34 mmol) in THF (5 mL) was treated with the cPrLi solution and BF3 etherate (115 pL, 0.914 mmol) in THE (1 mL) according to general procedure A. Epoxide A-I
(165 mg, 0.463 mmol) in THF (5 mL) was slowly added and the reaction slowly warmed to -30 C (-78 C: 1.5 h; -78 C to -50 C: 1.5 h; -500: 24 h; -50 C to -30 C: 40 min). Work-up and purification according to general procedure A
yielded B-I (150.7 mg, 82%).
Da = -38.8 (c = 0.50, CH2Cl2); 1H-NMR (CD2Cl2, 500.1 MHz) 5:
-0.16 (m, 1 H, cPr), 0.13-0.23 (m, 2 H, cPr), 0.34-0.43 (m, 2 H, cPr, H-3), 0.54-0.67 (m, 2 H, cPr, H-5a), 0.91 (m, 1 H, H-4a), 1.18 (m, 1 H, H-6a), 1.27-1.35 (m, 2 H, H-5b, H-6b), 1.44 (m 1 H, H-4b), 2.52 (s, 1 H, OH), 2.71 (ddd, 3J= 4.1, 8.6, 11.0 Hz, 1 H, H-1), 3.47 (t, 3J= 9.1 Hz, 1 H, H-2), 7.15-7.23, 7.42-7.43(2 m, 15 H, 3 C6H5); 13C-NMR (CD2Cl2, 125.8 MHz) 8: 0.85, 4.26, 14.56(3 C, cPr), 23.11 (C-5), 29.50 (C-4), 32.15 (C-6), 46.68 (C-3), 78.55 (C-2), 78.92 (C-1), 86.37 (0CPh3), 127.07, 127.73, 128.82, 145.37 (18 C, 3 C6H5); IR (KBr) v: 3571 (m, OH), 3058 (w), 2930 (m), 2858 (m), 1596 (vw), 1490 (m), 1448 (s), 1284 (w), 1225 (w), 1152 (w), 1063 (vs), 926 (w), 844 (vw), 824 (vw), 761 (m), 746 (m), 707 (vs) cm-1; elemental analysis calcd (%) for C26H3002 (398.54): C 84.38, H 7.59; found: C 84.16, H 7.78.

1(1R,2R,3R)-3-Cyclopropv1-1-hydroxv-cyclohex-2-v112,3,4-tris-0-benzvl-6-deoxv-a-L-galactoovranoside (B-II).
According to general procedure B, A-III (223 mg, 0.466 mmol) in CH2Cl2 (1.5 mL) was treated with a solution of Br2 (27.5 pL, 0.535 mmol) in CH2Cl2 (1 mL) for 30 min at 0 C. After destroying the excess of bromine, the fucosyl bromide solution was added to a solution of B-I (142 mg, 0.356 mmol) and Et4NBr (98.9 mg, 0.471 mmol) in DMF/CH2Cl2 (6 mL, 1:1), which has been stirred with activated 3A molecular sieves (1 g) for 4 h. The reaction was stirred for 67 h at r.t. and then quenched with pyridine (1 mL). Work-up and purification according to general procedure B yielded the tritylether (237 mg).
To a stirred solution of the tritylether in CH2Cl2 (4 mL), ZnBr2 (193 mg, 0.859 mmol) and triethylsilane (70 pL, 0.441 mmol) were added. The reaction was quenched after 1.75 h by adding H20 (100 pL). Work-up and purification according to general procedure B yielded B-II (136 mg, 67% over two steps) as a colorless solid.
[a]D21 = -29.0 (c = 0.65, CHCI3); 1H-NMR (CDCI3, 500.1 MHz) 5:
-0.06 (m, 1 H, cPr), 0.08 (m, 1 H, cPr), 0.22 (m, 1 H, cPr), 0.33 (m, 1 H, cPr), 0.87 (m, 1 H, H-4a), 0.96 (m, 1 H, cPr), 1.05-1.27 (m, 6 H, Fuc H-6, H-3, H-5a, H-6a), 1.54 (m, 1 H, H-4b), 1.64 (m, 1 H, H-5b), 1.96 (m, 1 H, H-6b), 3.11 (t, 3J= 9.1 Hz, 1 H, H-2), 3.35 (m, 1 H, H-1), 3.69 (m, 1 H, Fuc H-4), 3.98 (dd, 3JF3,F4 = 2.5 Hz, 3.-/F2,F3 = 10.1 Hz, 1 H, Fuc H-3), 4.11-4.16 (m, 2 H, Fuc H-2, Fuc H-5), 4.66-4.68 (m, 2 H, CH2Ph), 4.76, 4.77, 4.90, 5.01 (4 m, 4 H, CH2Ph), 5.14 (d, 3.-/F1,F2 = 3.4 Hz, 1 H, Fuc H-1), 7.26-7.41 (m, 15 H, 3 C6H5); 13C-NMR
(CDCI3, 125.8 MHz) 6: 0.76, 4.93, 13.58(3 C, cPr), 16.56 (Fuc C-6), 22.86 (C-5), 28.32 (C-4), 32.56 (C-6), 44.14 (C-3), 67.64 (Fuc C-5), 73.14, 73.19 (2 CH2Ph), 73.95 (C-1), 74.85 (CH2Ph), 76.74 (Fuc C-2), 77.68 (Fuc C-4), 78.63 (Fuc C-3), 92.33 (C-2), 99.20 (Fuc C-1), 127.42, 127.45, 127.50, 127.64, 128.18, 128.22, 128.35, 128.44, 138.44, 138.58, 138.90 (18 C, 3 C6H5); IR
(KBr) v: 3426 (s, OH), 3031 (vw), 3004 (vw), 2933 (s), 1497 (vw), 1453 (m), 1348(w), 1247 (vw), 1212 (vw), 1161 (m), 1136(s), 1103 (vs), 1064 (vs), 1026 (vs), 957 (w), 911 (vw), 843 (vw), 736 (s), 696 (s) cm-1; elemental analysis calcd (%) for C36H4406 (572.73): C 75.50, H 7.74; found: C 75.38, H 7.75.
{(1R,2R,3R)-2-[(2,3,4-tris-0-benzy1-6-deoxy-a-L-galactopyranosynoxv]-3-cyclopropyl-cyclohex-1-y1} 2,4,6-tri-O-benzoy1-3-0-f(1S)-1-benzvloxvcarbonv1-2-cyclohexyl-ethy11-0-b-galactooyranoside (B-III).
According to general procedure C, thioglycoside A-Vl (228 mg, 0.292 mmol) and glycosyl acceptor B-II (129 mg, 0.225 mmol) in dry CH2C12 (8 mL) were added via syringe to activated 3A molecular sieves (2 g). A
suspension of DMTST (177 mg, 0.685 mmol) and activated 3A molecular sieves (1 g) in CH2C12 (4 mL) was prepared in a second flask. Both suspensions were stirred at r.t. for 4 h, then the DMTST suspension was added via syringe to the other suspension with some additional CH2C12 (2 mL). The reaction was stopped after 48 h and work-up and purification according to general procedure C afforded B-III (253 mg, 87%) as a colorless foam.
[4)21 = -43.1 (c = 0.61, CHC13); 1H-NMR (CDC13, 500.1 MHz) 8:
-0.11 (m, 1 H, cPr), 0.16 (m, 1 H, cPr), 0.32-0.35 (m, 2 H, cPr), 0.46-0.53 (m, 2 H, CyCH2), 0.64-1.46 (m, 18 H, CyCH2, Cy, cPr), 1.38 (d, 3JF5,F6 = 6.4 Hz, 3 H, Fuc H-6), 1.80 (m, 1 H, H-6b), 3.52 (t, 3J = 7.3 Hz, 1 H, H-2), 3.57 (s, 1 H, Fuc H-4), 3.62 (m, 1 H, H-1), 3.84 (dd, 3JG3,G4 = 2.8 Hz, 3JG2,G3 = 9.8 Hz, 1 H, Gal H-3), 3.93 (m, 1 H, Gal H-5), 4.03 (dd, 3JF1,F2 = 3.2 Hz, 3JF2,F3 = 10.2 Hz, 1 H, Fuc H-2), 4.07 (dd, 3JF3,F4 = 1.7 Hz, 3*-IF2,F3 = 10.4 Hz, 1 H, Fuc H-3), 4.13 (dd, 3J = 4.5, 7.8 Hz, 1 H, Lac H-2), 4.32-4.40 (m, 3 H, Gal H-6, CH2Ph), 4.53 (m, H, CH2Ph), 4.58 (d, 3JG1, G2 = 8.1 Hz, 1 H, Gal H-1), 4.62, 4.68 (2 m, 2 H, CH2Ph), 4.74-4.76 (m, 2 H, Fuc H-5, CH2Ph), 4.78 (m, 1 H, CH2Ph), 5.05, 5.11 (2 m, 2 H, CH2Ph), 5.35 (d, 3JF1,F2 = 2.8 Hz, 1 H, Fuc H-1), 5.61 (m, 1 H, Gal H-2), 5.87 (m, 1 H, Gal H-4), 7.20-7.36, 7.42-7.44, 7.52-7.59, 8.03-8.14 (4 m, H, 7 C6H5); 13C-NMR (CDCI3, 125.8 MHz) 8: 3.06 (cPr), 5.26 (cPr), 13.55 (cPr), 16.81 (Fuc C-6), 20.97, 25.46, 25.72, 26.07, 27.71, 29.44, 32.62, 33.21, 33.40 (9 C, CyCH2, Cy), 40.46 (Lac C-3), 45.35 (C-3), 62.50 (Gal C-6), 66.34 30 (Fuc C-5), 66.61 (CH2Ph), 70.10 (Gal C-4), 71.49 (Gal C-5), 72.13 (CH2Ph), 72.32 (Gal C-2), 74.22 (CH2Ph), 74.87 (CH2Ph), 76.15 (Fuc C-2), 77.97 (Gal C-3), 78.38 (Lac C-2), 78.82 (C-2), 79,13 (Fuc C-4), 79.66 (C-1), 79.83 (Fuc C-3), 97.02 (Fuc C-1), 99,60 (Gal C-1), 126.96, 127.05, 127.20, 127.38, 127.78, 128.05, 128.09, 128.37, 128.43, 128.47, 128.53, 129.61, 129.73, 129.89, 129.93, 129.96, 133.03, 133.16, 133.23, 135.44, 138.51, 138.95, 139.21 (42 C, 7 C6H5), 164.57, 165.98, 166.16, 172.43(4 C=0); IR (kBr) v: 3064 (vw), 3032 (vw), 2927 (s), 2854 (w), 1731 (vs, CO), 1602 (vw), 1497 (vw), 1452 (m), 1315 (m), 1267 (vs), 1176 (s), 1097 (vs), 1027 (vs), 840 (vw), 713 (vs) cm;
elemental analysis calcd (%) for C701016 (1291.52): C 73.47, H 6.71; found: C
73.32, H 6.81.
R2R.3R)-3-cyclopropy1-2-1I6-deoxy-ct-L-galfictopyranosvIloxvi-Cvclohex-111) ?-0-b nzov1-3-04(1M-1-carboxv-2-cyclohexvi-ethv11-13-o-rialactopyranoside (B-IV: Fig. 4).
8-111 (100 mg, 77.7 mot) was hydrogenated with Pd(OH)2/C (52 mg, 10% Pd) in dioxane/H20 (4:1, 3.75 mL) according to general procedure D.
After 24 h the mixture was filtered through celit:and hydrogenated with fresh Pd(OH)21C (50 mg) for another 48 h. The reaction mixture was filtered through celittand evaporated to dryness. The residue was redissolved in methanol (5 mL) and sodium methoxide (194 pmol in 190 pl !MOH) was added. After stirring at r.t. for 16h the reaction was quenched by addition of acetic add (22 pL), The mixture was concentrated in vacuo and purified by preparative, reversed-phase HPLC to afford B-1V (40.5 mg, 72%) as a colorless solid, [a]D21 -85.4 (c = 0.75, Me0H); 1H-NMR (Me0D, 5001 MHz) 8:
-0.04 (m, 1 H, cPr), 0.33 (m, 1 H, cPr), 0A5-0.52 (m, 2 11, cPr), 0.56-1.65 (m, 20 H, CyCH2, cPrCy), 1.30 (d, 3.ks,Fe = 6.6 Hz, 3 H, Fuc H-6), 1.94 (m, 1 H, H-6b), 3.45 (t, 3J = 8.5 Hz, 1 H, H-2), 3.56 (m, 1 H, Gal H-5), 3.62 (m, 1 H, H-1), 3.66 (dd, 3,./G3,G4 = 3.1 Hz,342,03= 9.8 Hz, 1 H, Gal H-3), 3.71-3.74 (m, 2 H, Gal H-60, Fuc H-2), 3.78 (m, 1 H, Fuc H-4), 3.83 (dd, 3Jc,5,c6b = 7.1 Hz, 2Jce0,c6b = 11.4 Hz, 1 H, Gal H-6b), 3,95 (dd, 3JF3,F4 = 3.3 Hz,3../F2.F3 =
10,2 Hz, 1 H, F1.1C H-3), 3.97 (m, 1 H, Gal H-4), 4.06 (dd, 3J = 2.9, 9.8 Hz, 1 H, Lac 142), 4.66 (d, 3JG1G2 = 8.0 Hz, 1 H, Gal H-1), 4.88 (m, 1 H, Fuc H-5), 5.37 (d, = 3.9 Hz, 1 H, Fuc H-1), 5.39 (dd, 3JG1,G2 = 8.1 Hz, 3JG2,G3 = 9.6 Hz, 1 H, Gal H-2), 7.49-7.52, 7.61-7.65, 8.07-8.09 (3 m, 5 H, C6H5); 13C-NMR (Me0D, 125.8 MHz) 8: 3.96, 7.18, 15.53 (3 C, cPr), 16.72 (Fuc C-6), 22.94, 26.54, 26.73, 27.27, 30.78, 31.45(6 C, CyCH2, Cy), 33.13, 34.20, 35.07, 42.76 (4 C, CyCH2), 48.49 (C-3), 62.72 (Gal C-6), 67.61 (Fuc C-5), 67.88 (Gal C-4), 70.24 (Fuc C-2), 71.34 (Fuc C-3), 73.16 (Gal C-2), 73.97 (Fuc C-4), 76.02 (Gal C-5), 78.01 (Lac C-2), 80.29 (C-1), 80.52 (C-2), 83.45 (Gal C-3), 98.97 (Fuc C-1), 100.41 (Gal C-1), 129.66, 130.82, 131.63, 134.36(6 C, C6H5), 166.76 (C=0), 178.83 (CO2H); HR-MS (ESI) m/z: calcd for C37H54Na014 [M+Na]: 745.3406;
found: 745.3407 (0.1 ppm).

{(1R,2R,3S)-3-BUTYL-2-[(6-DEOXY-a-L-GALACTOPYRANOSYL)OXY]-CYCLOHEX-1-YL}
2-0-BENZ0YL-3-04( 1 S)-1 -CARBOXY-2-CYCLOH EXYL-ETHYL]-13-D-GALACTOPYRANOSIDE SODIUM SALT (C-IV; FIG. 5) (1R,2R,3S)-3-Butyl-1-0-triphenylmethyl-cyclohexane-1,2-diol (C-I).
CuCN (342 mg, 3.81 mmol) in THF (10 mL) was treated with nBuLi (2.5 M in hexane, 3.05 mL, 7.63 mmol) and BF3 etherate (192 pL, 1.53 mmol) in THE (2 mL) according to general procedure A. Epoxide A-I (271 mg, 0.761 mmol) in THF (8 mL) was slowly added and the reaction slowly warmed to -30 C (-78 C: 1 h; -78 C to -50 C: 4 h; -50 : 24 h; -50 C to -30 C: 21 h).
Work-up and purification according to general procedure A yielded C-I (220 mg, 70%).
[a]D21 = -37.8 (c = 0.66, CHCI3); 1H-NMR (CDCI3, 500.1 MHz) 8:
0.73 (m, 1 H, H-5a), 0.85 (m, 1 H, H-4a), 0.86 (t, 3J = 7.2 Hz, 3 H, H-10), 1.03-1.16 (m, 3 H, H-3, H-7a, H-8a), 1.21-1.35 (m, 4 H, H-6a, H-8b, H-9a, H-9b), 1.38-1.49 (m, 2 H, H-5b, H-6b), 1.61 (m, 1 H, H-4b), 1.75 (m, 1 H, H-7b), 2.70 (s, 1 H, OH), 2.82 (ddd, 3J = 4.0, 8.6, 11.2 Hz, 1 H, H-1), 3.40 (t, 3J = 9.0 Hz, 1 H, H-2), 7.21-7.30, 7.48-7.50 (2 m, 15 H, 3 C6H5); 13C-NMR (CDCI3, 125.8 MHz) 8:

14.11 (C-10), 23.10 (C-9), 23.37 (C-5), 28.73 (C-8), 29.38 (C-4), 32.05 (C-7), 32.30 (C-6), 42.45 (C-3), 77.62 (C-2), 79.05 (C-1), 86.43 (CPh3), 127.05, 127.74, 128.70, 145.12 (18 C, 3 C6I-15); elemental analysis calcd (%) for C291-13402 (414.58): C 84.02, H 8.27; found: C 84.05, H 8.27.
J(1R2R,3S)-3-Butv1-1-hydroxy-cyclohex-2-v112,3,4-tris-0-benzy1-6-deoxy-a-L-qalactopyranoside (C-ID.
According to general procedure B, A-III (308 mg, 0.644 mmol) in CH2Cl2 (3 mL) was treated with a solution of Br2 (38 pL, 0.740 mmol) in CH2Cl2 (1 mL) for 30 min at 0 C. After destroying the excess of bromine, the fucosyl bromide solution was added to a solution of C-I (205 mg, 0.495 mmol) and Et4NBr (137 mg, 0.650 mmol) in DMF/CH2Cl2 (10 mL, 1:1), which has been stirred with activated 3A molecular sieves (700 mg) for 3.5 h. The reaction was stirred for 67 h at r.t. and then quenched with pyridine (1 mL). Work-up and purification according to the general procedure B yielded the tritylether (283 mg) as a yellowish resin. To a stirred solution of the tritylether in CH2Cl2 (4 mL), ZnBr2 (229 mg, 1.02 mmol) and triethylsilane (81 pL, 0.510 mmol) were added. The reaction was quenched after 1.25 h by adding H20 (100 pL).
Work-up and purification according to general procedure B yielded C-I1 (161 mg, 55% over two steps) as a colorless solid.
[a]D21 = -21.3 (c = 0.56, CHCI3); 1H-NMR (CDCI3, 500.1 MHz) 8:
0.82 (t, 3J= 7.0 Hz, 3 H, H-10), 0.86 (m, 1 H, H-4a), 0.98 (m, 1 H, H-7a), 1.15 (d, 3JF5,F6 = 6.5 Hz, 3 H, Fuc H-6), 1.09-1.37 (m, 7 H, H-3, H-5a, H-6a, H-88, H-8b, H-9a, H-9b), 1.66 (m, 1 H, H-5b), 1.81 (m, 1 H, H-4b), 1.98 (m, 1 H, H-6b), 2.10 (m, 1 H, H-7b), 2.94 (t, 3J= 9.3 Hz, 1 H, H-2), 3.36 (m, 1 H, H-1), 3.68 (m, 1 H, Fuc H-4), 3.98 (dd, 3JF3,F4 = 2.6 HZ, 3JF2,F3 = 10.2 Hz, 1 H, Fuc H-3), 4.09-4.14 (m, 2 H, Fuc H-2, Fuc H-5), 4.65, 4.70, 4.75, 4.78, 4.85 (5 m, 5 H, 3 CH2Ph), 4.98-5.00 (m, 2 H, Fuc H-1, 1 CH2Ph), 7.25-7.39 (m, 15 H, 3 C6H5); 13C-NMR
(CDCI3, 125.8 MHz) 6:14.11 (C-10), 16.57 (Fuc C-6), 22.72 (C-9), 23.19 (C-5), 29.03 (C-8), 30.26 (C-4), 31.24 (C-7), 32.55 (0-6), 41.18 (C-3), 67.54 (Fuc C-5), 72.97 (CH2Ph), 73.26 (C-1), 73.39 (CH2Ph), 74.84 (CH2Ph), 76.38 (Fuc C-2), 77.60 (Fuc C-4), 78.80 (Fuc C-3), 91.47 (C-2), 98.31 (Fuc C-1), 127.40, 127.45, 127.52, 127.61, 127.86, 128.20, 128.21, 128.33, 128.38, 138.32, 138.44, 138.79 (18 C, 3 C6H5); elemental analysis calcd (%) for C37H4806 (588.77): C 75.48, H 8.22; found: C 75.55, H 8.28.
{(1R,2R3S)-2-[(2,3,4-tris-0-benzyl-6-deoxy-a-L-galactopyranosyl)oxy]-3-butyl-cyclohex-1-y1) 2,4,6-tri-O-benzoy1-3-0-1(1S)-1-benzvloxvcarbony1-2-cyclohexvl-ethv11-13-o-oalactopyranoside (C-III).
According to general procedure C, thioglycoside A-VI (218 mg, 0.279 mmol) and glycosyl acceptor C-I1 (126 mg, 0.215 mmol) in dry CH2Cl2 (8 mL) were added via syringe to activated 3A molecular sieves (2 g). A
suspension of DMTST (166 mg, 0.644 mmol) and activated 3A molecular sieves (1 g) in CH2Cl2 (4 mL) was prepared in a second flask. Both suspensions were stirred at r.t. for 4.5 h, then the DMTST suspension was added via syringe to the other suspension with some additional CH2Cl2 (2 mL).
The reaction was stopped after 65.5 h and work-up and purification according to general procedure C afforded C-III (224 mg, 80%) as a colorless foam.
[a]D21 = -46.7 (c = 0.49, CHCI3); 1H-NMR (CDCI3, 500.1 MHz) 8:
0.45-1.84 (m, 26 H, CyCH2, nBuCy), 0.80 (d, 3J.6.8 Hz, 3 H, nBu), 1.40 (d, 3J=6.5 Hz, 3 H, Fuc H-6), 3.36 (t, 3J= 8.5 Hz, 1 H, H-2), 3.52 (s, 1 H, Fuc H-4), 3.54 (m, 1 H, H-1), 3.83 (dd, 3,-/G3,G4 = 3.0 Hz, 3JG2,G3 = 9.8 Hz, 1 H, Gal H-3), 3.92 (m, 1 H, Gal H-5), 4.01 (dd, 3,-/F1,F2 = 3.2 Hz,3JF2,F3 = 10.3 Hz, 1 H, Fuc H-2), 4.04 (dd, 3JF3,F4 = 2.0 Hz, 3JF2,F3 = 10.4 Hz, 1 H, Fuc H-3), 4.13 (dd, 3J = 4.6, 7.8 Hz, 1 H, Lac H-2), 4.28 (dd, 3Jc5,G6a = 6.7 Hz,./
2¨G6a,G6b = 11.4 Hz, 1 H, Gal H-6a), 4.28 (m, 1 H, CH2Ph), 4.39 (dd, 3JG5,G6b = 5.8 Hz,./
2¨G6a,G6b = 11.4 Hz, 1 H, Gal H-6b), 4.52 (m, 1 H, CH2Ph), 4.56 (d, 3Jc1,G2 = 8.1 Hz, 1 H, Gal H-1), 4.65, 4.68, 4.74, 4.76 (4 m, 4 H, CH2Ph), 4.79 (m, 1 H, Fuc H-5), 5.01 (d, = 3.0 Hz, 1 H, Fuc H-1), 5.05, 5.11 (2 m, 2 H, CH2Ph), 5.61 (m, 1 H, Gal H-2), 5.85 (m, 1 H, Gal H-4), 7.20-7.36, 7.42-7.46, 7.52-7.59, 8.04-8.13 (4 m, H, 7 C6I-15); 13C-NMR (CDCI3, 125.8 MHz) 5: 14.26 (CH2CH2CH2CH3), 16.81 30 (Fuc C-6), 21.84, 22.95, 25.46, 25.71, 26.07, 28.34, 28.55, 30.20, 30.39, 32.61, 33.19, 33.39,40.48, 42.80 (14 C. CyC1I2, nEtuCy), 62.52 (Gal C-6), 66.37 (Fuc C-5), 66.63 (CH2Ph), 70.15 (Gal C-4). 71.45 (Gal C-5), 72.11 (CH2Ph), 72.21 (Gal C-2), 73.89, 74.92 (2 CH2Ph), 76.17 (Fuc C-2), 78.05 (Gal C-3), 78.38 (Lac C-2), 78.76 (C-2), 79.23 Fuc C4), 79.75 (Fuc-3), 80.79 (C-1), 97.71 (Fuc C-1), 100.03 (Gal C-1), 126.95, 127.04, 127.21, 127.30, 127,80, 128.04, 128.09, 128.15, 128.39, 128.44, 128.48, 128.49, 12854,12966, 129.71, 129.75, 129,92, 129.94, 133.03, 133.16, 133.25, 135,42, 138.70, 138.99, 139.16 (42 C. 7 C8H5), 164.56, 166.09, 166.21, 17247 (4 CO), elemental analysis calcd (%) for C8419018 (1307.54 C 73.49, H 6.94; found: C 73.16, H
6.93.
R.2R,3S)-3-buty1-24(6-deoxy-a-i-galactopyranosynoxyl-cyclohex-111) 2-0-benzov1-3-0-[(18)-1-carboxy-2-cyclohexyl-ethvII-D-o-aalactopyrari sid sodium salt (C-IV: Fig. 5).
CM (100 mg, 765 pmol) was hydrogenated with Pd(OH)2IC (50 mg, 10% Pd) in dioxane/H20 (4:1, 3.75 mt.) according to general procedure D.
After 19 h the mixture was filtered through celite and hydrogenated with fresh Pd(OH)2/C (50 mg) for another 30 h. The reaction mixture was filtered through 4It celite and evaporated to dryness. The residue was redissolved in methanol (5 mi..) and sodium methoxide (0.191 mmol) was added. After stirring at r.t. for h the reaction was quenched by addition of acetic acid (22 pL). The mixture was concentrated in vacua and purified by column chromatography *
(CH2C12/methanollwater, 3.4;1:0.1 to 2:1 :0.1), followed by Dowex 50 (Na4 form) ion exchange column, Sephadex G15 column, microfiltration and lyophilization from dioxane to give C-N (32.3 mg, 56%) as a colorless foam. For biological testing a small amount was purified by preparative, reversed-phase HPLC to afford the free acid of C-IV as colorless needles.
C-IV sodium salt: [431021 = -77.9 (c =0.61, Me0H); 1H-NMR
(Me0D, 500.1 MHz) 8: 0.47-1.89 (m,25 H, CyCH2, nEiu, Cy), 0.$8(t, 3õ1= 7.1 Hz, 3 H, neu), 1.31 (d, 3J = 6.5 Hz, 3 H, Fuc H-6), 2.00 (m, 1 Hi H-6b), 3.24 (t, 3../ = 8.9 Hz, 1 H, H-2),3.56-3.60 (rn, 2H, Gal H-5, Gal H-3), 3.65 (m, 1 H, H-1), *Ttademark 3.72-3.77 (m, 4 H, Gal H-6a, Fuc H-2, Fuc H-4, Lac H-2), 3.80 (dd, 3JG5,G6b =
6.9 Hz, 2u/G6a,G6b 11.5 Hz, 1 H, Gal H-6b), 3.88 (dd, 3JF3,F4 = 3.3 Hz, 3JF2,F3 =
10.3 Hz, 1 H, Fuc H-3), 3.95 (m, 1 H, Gal H-4), 4.68 (d, 3JG1,o2 = 8.1 Hz, 1 H, Gal H-1), 4.85 (m, 1 H, Fuc H-5), 4.94 (d, 3JF1,F2 = 4.0 Hz, 1 H, Fuc H-1), 5.41 (dd, 3Joio2 = 8.5 Hz, 3,-/G2,G3 = 9.2 Hz, 1 H, Gal H-2), 7.48-7.51, 7.60-7.63, 8.07-8.09 (3 m, 5 H, C6H5); 13C-NMR (Me0D, 125.8 MHz) 5: 14.48 (nBu), 16.72 (Fuc C-6), 23.27, 23.92, 26.57, 26.82, 27.41, 29.83, 30.04, 31.69, 31.86, 33.06, 34.44, 35.41, 43.54, 44.30 (14 C, nBu, Cy, CH2Cy), 63.06 (Gal 0-6), 67.70 (Gal C-4), 67.84 (Fuc 0-5), 70.21 (Fuc C-2), 71.34 (Fuc 0-3), 73.08 (Gal C-2), 73.90 (Fuc C-4), 75.92 (Gal C-5), 80.69 (Lac C-2), 80.41 (C-1), 81.37 (C-2), 83.69 (Gal C-3), 99.91 (Fuc C-1), 100.53 (Gal C-1), 129.60, 130.84, 131.76, 134.23(6 C, C6H5), 166.87 (C=0), 183.26 (COOH); HR-MS (ESI) m/z: calcd for C381-158Na014 [M+H]: 761.3719; found: 761.3710 (1.2 ppm).
C-IV free acid:1H-NMR (Me0D, 500.1 MHz) 8: 0.54-1.91 (m, 25 H, CyCH2, nBu, Cy), 0.89 (t, 3J= 7.1 Hz, 3 H, nBu), 1.32 (d, 3J= 6.6 Hz, 3 H, Fuc H-6), 1.98 (m, 1 H, H-6b), 3.23 (t, 3J = 8.9 Hz, 1 H, H-2), 3.56 (m, 1 H, Gal H-5), 3.62 (m, 1 H, H-1), 3.66 (dd, 3Jo3,o4 = 3.0 Hz,3JG2,G3 = 9.8 Hz, 1 H, Gal H-3), 3.70-3.75 (m, 3 H, Gal H-6a, Fuc H-2, Fuc H-4), 3.79 (dd, 3JG6b,G5 = 6.9 Hz, 2JG6a,G6b = 11.3 Hz, 1 H, Gal H-6b), 3.85 (dd, 3JF3,F4 = 3.3 Hz, 3JF2,F3 =
10.3 Hz, 1 H, Fuc H-3), 3.97 (m, 1 H, Gal H-4), 4.06 (dd, 3J= 2.9, 9.9 Hz, 1 H, Lac H-2), 4.67 (d, 3Jc1,o2 = 8.1 Hz, 1 H, Gal H-1), 4.88-4.92 (m, 2 H, Fuc H-1, Fuc H-5), 5.43 (dd, 3Jo1,o2= 8.2 Hz, 3Jo2,o3= 9.6 Hz, 1 H, Gal H-2), 7.49-7.52, 7.62-7.64, 8.07-8.09 (3 m, 5 H, C6H5); 13C-NMR (Me0D, 125.8 MHz) 8: 14.48 (nBu), 16.74 (Fuc C-6), 23.38, 23.90, 26.54, 26.72, 27.28, 29.83, 29.99, 31.71, 31.81, 33.12, 34.19, 35.07, 42.78, 44.51 (140, nBu, Cy, CH2Cy), 62.69 (Gal 0-6), 67.79 (2 C, Fuc C-5, Gal C-4), 70.27 (Fuc C-2), 71.43 (Fuc C-3), 73.10 (Gal C-2), 73.94 (Fuc 0-4), 75.90 (Gal 0-5), 77.93 (Lac C-2), 80.71 (C-1), 81.45 (C-2), 83.57 (Gal C-3), 100.29 (Fuc C-1), 100.52 (Gal C-1), 129.67, 130.85, 131.63, 134.37 (6 C, C6H5), 166.77 (C=0), 178.84 (CO2H).

((I R,2R3R)-2-{(6-0EOXY-a-L-GALACTOPYRANOSYL)OXY}3-(24AETHOXYCARBONYL-ETHYLYCYCLOHEX-1-YL) 2-0-BEIVOYL-3-0-1(1S)-1-CARBOXY-2-CYCLOHEXYL-ETHYL1-13-0-GALACTOPYRANOSIDE (0-111; FIG. 6) 6 1(1R2R3R)-1-Hydroxy-3-(2-methoxycarbonyl-ethyl)-cyclohex-2-vil 2.4-tris-O-benzy1-6-clw,xy-tx-t-galactoovranoside (04).
A-IV (106 mg, 0.189 mina was dissolved in CH2C12 (5 mi.) and Grubbs cat 2nd gen. (16.0 mg 18.8 limo!) and methyl acrylate (171 pL, 1.90 mmol) were added. The reaction was heated under reflux for 96. After 1 d, 2 d and 7 d additional Grubbs cat. 2nd gen. (each 16.0 mg, 18.8 pmol) and methyl acrylate (each 171 pL, 1.90 mmol) were added. The mixture was concentrated under reduced pressure and purified by column chromatography (petroleum ether/ethyl acetate, 5:1 to 4:1) to yield an Ea mixture (53.9 mg), which was directly used for hydrogenation. A solution of the Ea-mixture in THE (4 mL) was added to Pd/C (28.0 mg, 10% Pd) under argon. The mixture was hydrogenated under atmospheric pressure at Lt. After 30 min the reaction was filtered through mike, concentrated under reduced pressure and purified by column chromatography (petroleum ether/ethyl acetate, 3:1 to 2:1) to yield 0-1 (29.1 mg, 25%) as a brownish oil.
[a]D21 = -21.2 (c = 1.46, CHCI3); 1H-NMR (CDCI3, 500.1 MHz) 8:
0.94 (m, 1 H), 1.14 (d, 3JF6,F5 = 6.5 Hz, 3 H, Fuc H-6), 1.19-1.28 (m, 2 H), 1.35-1.47 (m, 2 H), 1.67 (m, I H), 1.74 (m, I H), 1.99 (m, 1 H), 2.29-2.36 (m, H), 2.97 (t, 3.1= 9.2 Hz, 1 H, H-2), 3.36 (m, I H, H-1), 3.57 (s, 3 H, Me), 3.67 (in, 1 H, Fuc H-4), 3.98 (dozl, 3dF3.F4 = 2.4 Hz, 34k2,F3 = 10.2 Hz, I H, Fuc H-3), 4.09-4.13 (m, 2 H, Fuc 11-2, Fuc 11-5), 4.65,4.71, 4.76,4.78, 4.85(5 in, 511, CH2Ph), 4.96 (d, 3,./F1,F2 = 3.4 Hz, 1 H, Ric H-1), 4.99 (1 m, 1 H, CH2Ph).
7.25-7.41 (m, 15 H, 3 Cot-I5); 13C-NMR (CDCI3, 125.8 MHz) 6:16.50 (Fuc C-6), 23.03, 2748, 30.37, 32.02, 3233(5 C), 40.72 (C-3), 51.30 (Me), 67.64 (Fuc C-5), 72.97, 73.00 (CH2Ph, C-1), 73.48, 74.82(2 CH2Ph), 76.01 (Fuc C-2), 77.50 (Fuc C-4), 78.84 (Fuc C-3), 9125 (C-2), 98.33 (Fuc C-1), 127.43, 12747, *Trademark 127.58, 127.62, 127.92, 128.19, 128.28, 128.34, 128.36, 138.23, 138.36, 138.73 (18 C, 3 C6H5), 174.33 (COOMe); HR-MS (ESI) m/z: calcd for C37H46Na08 [M+Na]: 641.3085; found: 641.3080 (0.8 ppm).
{(1R,2R,3R)-21(2,3,4-tris-0-benzyl-6-deoxy-a-L-qalactopvranosvpoxv1-3-(2-methoxycarbonyl-ethvI)-cyclohex-1-yll 2,4,6-tri-O-benzoy1-3-04(1S)-1-benzyloxycarbony1-2-cyclohexvl-ethyll-13-o-galactopyranoside (D-II) According to general procedure C, thioglycoside A-VI (47.9 mg, 61.3 pmol) and glycosyl acceptor D-I (29.1 mg, 47.0 pmol) in dry CH2Cl2 (4 mL) were added via syringe to activated 3A molecular sieves (500 mg). A
suspension of DMTST (37.6 mg, 146 pmol) and activated 3A molecular sieves (250 mg) in CH2Cl2 (2 mL) was prepared in a second flask. Both suspensions were stirred at r.t. for 4 h, then the DMTST suspension was added via syringe to the other suspension with some additional CH2Cl2 (1 mL). The reaction was stopped after 65.5 h and work-up according to general procedure C and purification by column chromatography (petroleum ether/ethyl acetate, 4:1 to 3:1) afforded D-I1 (49.5 mg, 79%) as a colorless foam.
{ociD21 = _38.1 (c = 0.59, CHCI3); 1H-NMR (CDCI3, 500.1 MHz) :
0.45-1.57 (m, 19 H, CyCH2, Cy), 1.37 (d, 3J= 6.4 Hz, 3 H, Fuc H-6), 1.61 (m, 1 H, (CH2)2CO2Me), 1.82 (m, 1 H, H-6b), 2.13-2.26 (m, 3 H, (CH2)2CO2Me), 3.39 (t, 3J = 8.1 Hz, 1 H, H-2), 3.51 (s, 1 H, Fuc H-4), 3.53-3.56 (m, 4 H, H-1, Me), 3.84 (dd, 3JG3,c4 = 3.3 Hz,3JG2,G3 = 9.9 Hz, 1 H, Gal H-3), 3.93 (m, 1 H, Gal H-5), 3.98-4.03 (m, 2 H, Fuc H-2, Fuc H-3), 4.13 (dd, 3J= 4.5, 8.0 Hz, 1 H, Lac H-2), 4.28 (dd, 3JG5,G6a = 7.2 Hz, 2.../G6a,G6b = 11.4 Hz, 1 H, Gal H-6a), 4.31 (m, 1 H, CH2Ph), 4.38 (dd, 3.-/G5,G6b = 5.6 Hz, ./
2¨G6a,G6b = 11.4 Hz, 1 H, Gal H-6b), 4.54 (m, 1 H, CH2Ph), 4.55 (d, 3JG1,G2 = 8.0 Hz, 1 H, Gal H-1), 4.66-4.71 (m, 3 H, CH2Ph, Fuc H-5), 4.73, 4.77 (2 m, 2 H, CH2Ph), 5.02 (d, 3JF1,F2 = 2.3 Hz, 1 H, Fuc H-1), 5.05, 5.12(2 m, 2 H, CH2Ph), 5.60 (m, 1 H, Gal H-2), 5.85 (m, 1 H, Gal H-4), 7.19-7.34, 7.42-7.47, 7.53-7.59, 8.03-8.13 (4 m, 35 H, 7 C6H5);
13C-NMR (CDCI3, 125.8 MHz) 6:16.78 (Fuc C-6), 21.18, 25.44, 25.66, 25.70, 26.05, 27.84, 31.26, 32.57, 33.19, 33.38, 40.45 (12 C, CyCH2, Cy, WO 2008/060378 Per/US2007/021541 (CH2)2CO2Me), 41.94 (C-3), 51.42 (CO2Me), 62_54 (Gal C-6), 66.50 (Fuc C-5), 66.62 (CH2Ph), 70.09 (Gal C-4), 71.48 (Gal C-5), 72.24(2 C. CH2Ph, Gal C-2), 73.79, 74.90 (2 CH2Ph), 76.26 (Fuc C-2), 77.91 (Gal C-3), 7834, 78.38 (Lac C-2, C-2), 79.09 (Fuc C-4), 79.53 (Fuc C-3), 80.22 (C-1), 97.70 (Fuc C-1) 99.93 (Gal C-1), 126.96, 127.06, 127.23, 127.29, 127.83, 128.04, 128.06, 128.08, 128.15, 128.38, 128.44, 128.48, 128.53,128.57, 129.62, 129.65, 129.69, 129.74, 129.86, 129.88, 129,94, 129.99, 133.05, 133.19, 133.24, 135.39, 138.64, 138.99, 139.07 (42 C, 7 C6H5), 164.55, 166.06, 166.17,172.45, 174.02 (5 C=0); elemental analysis calcd (%) for CaoH08018 (1337.54): C 71.84, H
6.63; found: C71.70, H 6.73.
4(1R,2R,3R)-2-4(6-leoxy-ce.-L-oalactooyranosynoxv1-3-(2-methoxycarbonvl-ethyl)-cyclohex-1-v112-0-benzoy1-3-04(1S)4-carboxv-2-cyclohexvi-ethyl1-P-o-galactopyranoside (13-10: Fig.
D-Ill (46.0 mg, 344 pmol) was hydrogenated with Pd(OH)2/C (25 mg, 10% Pd) in dioxane/1-120 (4:1, 3.75 mL) according to general procedure D.
After 42 h the mixture was filtered through cellte and hydrogenated with fresh Pd(OH)2/C (27 mg) for additional 24 h. The reaction mixture was filtered 4, through celite and evaporated to dryness. The residue was redissolved in methanol (3 mL) and sodium methoxide (51.6 pmol in 55 p1Me0H) was added.
After stirring at r.t. for 16 h the reaction was quenched by addition of acetic acid (6 pL). The mixture was concentrated in vacuo and purified by preparative, reversed-phase HPLC to afford D-111(19.2 mg, 73%) as a colorless solid, 0.63, Me0H); 1H-NMR (Me0D, 500.1 MHz) 8:
0.55-0.75 (m, 4 H, CyCH2), 0.84-0.96 (m, 2 H, CyCI-12, H-4a), 1.04 (m, 1 H, H-6a), 1.14(m, I H, 1.21-1.36 (m, 5 H, CyCH2), 1.32 (d,3,/ = 6.6 Hz, 3 H, Fuc H-6), 139-1.60 (m, 6 H, CyCH2, H-3, H-5b, (CH2)2002Me), 1.66 (m, 1 H, H-4a), 1.97 (m, 1 H, H-6b), 2.18-2.38 (m, 3 H, CyCH21 (CH2)2CO2Me), 3.27 (t, 3J= 8.4 Hz, 1 H, H-2), 3.57(m, 1i-I, Gal H-5), .63-3.68(m,3 5 H, CH3, Gal H-3, H-1), 3_71-3.75 (m, 3 H, Gal H-6., Fuc H-2, Ftic H-4), 3.79 (dd, 3JG5,Geb =
6,8 Hz,J
2-03a,G613 = 11.3 Hz, 1 H, Gal H-6b), 3.84 (dd, 3,./F3,F4 = 3.3 Hz, 3JF2,F3 =
10.2 *Trademark Hz, 1 H, Fuc H-3), 3.98 (m, 1 H, Gal H-4), 4.07 (dd, 3J = 3.0, 9,9 Hz, 1 H, Lac H-2), 4.67 (d, 3JG1,02 = 81 Hz, 1 H, Gal H-1), 4.83 (m, 1 H, Fuc H-5), 4.92 (m, 1 H, Fuc H-1), 543 (dd, = 82 Hz, 3JG2,G3 = 9,6 Hz, 1 H, Gal H-2), 7,49-7.52, 7.62-7.65, 8.08-8.09 (3 m, 5H, C6H5); 13C-NMR (Me00, 125.8 MHz) 8; 16.73 (Fuc C-6), 22,77 (C-5), 26,55, 26.73, 2728, 2734(4 C, CyCH2), 29.49 (C-4), 31.34 (C-6), 32.16 ((CH2)2CO2Me), 33.13, 34.20, 35.07 (3 C, CyCH2), 42.78 ((CH2)2CO2Me), 43.52 (C-3), 52.03 (Me), 62.62 (Gal C-6), 67.81 (Gal C-4), 67.89 (Fuc C-5), 7025 (Fuc C-2), 71A1 (Fuc C-3), 73.09 (Gal C-2), 73.90 (Fuc C-4), 75.92 (Gal C-5), 77.98 (Lac C-2), 80.36 (C-1), 80.96 (C-2), 83.50 (Gal C-3), 100.34 (Fuc C-1), 100.50 (Gal C-1), 129.68, 130.85, 131.62, 134.39 (6 C, C6H5), 166.77, 176.09, 178,86 (3 C=0); elemental analysis calcd (%) for C30-166016 (768.84) + 1112 H20: C57.35, H 7.47; found: C 57.57, H 7.36;
HR-MS (ESI) m/z: calcd for C381-156Na0161M+Nar: 7913461; found: 791 3463 1!. (0.3 ppm).

{(1R,2R,5R)-5-7-ERr-Bunt-24(6-DEOXY-Ct-L-GALACTOPYRANOSYLPX*CYCLOHEX-1-Y1) 2-10-BENZOYL-3-0-0 SY1-CARBOXY-2-CYCLOHEXYL-ETHYL1-13-D-GALACTOPYRANOSIDE (E-Xl; FIG. 7) rac-(1S.2R.5,51-5-tert-Buty1-2-hydroxycycloheol benzoate (rac-E-IV) and rac-(16,2RAS)-4-tert-Euty1-2-hvdroxmclohexvlbenzoate (ac-E-V).
4-tert-Butylcatechol (E-1) (2.02 g, 12.2 rnmal), Rh/A1203 (98.9 mg).
cyclohexane (4 mL) and THF (0.5 mL) were hydrogenated under 5 bar at r.t.
After 24 h the mixture was filtered through celite and evaporated to dryness.
The residue was purified by MPLC on silica (CH2C12/ethyl acetate, 3:1 to 1:3) to 26 afford a mixture of syn-diols (1.64 g, 78%, rac-E-11:rac-E-III, 1.4:1) as a white solid. The mixture (1.64 9, 955 mmol) and dibutylfin oxide (2.37 9, 9.52 mmol) were dissolved in CH2C12 (50 mL) and cooled to 0 C. Et3N (2.68 mL, 19.2 mmol) and benzoyl chloride (1.32 mL, 11.45 mmol) were slowly added via syringe. The mixture was warmed to rt. during 3 h and then quenched with *Trademark =

Me0H (2 mL). The solvents were evaporated in vacuo and the crude residue was purified by MPLC on silica (toluene/ethyl acetate, 10:0 to 10:1) affording rac-E-IV (1.15 g, 44%) and rac-E-V (688 mg, 26%) as white solids.
rac-E-IV:1H-NMR (CDCI3, 500.1 MHz) 5: 0.90 (s, 9 H, tBu), 1.23 (m, 1 H, H-5), 1.42 (m, 1 H, H-4a), 1.50-1.57 (m, 2 H, H-3a, H-4b), 1.68 (m, 1 H, H-6a), 1.85 (m, 1 H, H-6b), 2.04 (m, 1 H, H-3b), 4.17 (m, 1 H, H-2), 5.05 (ddd, 3J = 2.7,4.7, 11.9 Hz, 1 H, H-1), 7.44-7.47, 7.56-7.59, 8.05-8.07 (3m, 5 H, C6H5); 13C-NMR (CDCI3, 125.8 MHz) 6:19.59 (C-4), 26.42 (C-6), 27.51 (3 C, tBu), 30.57 (C-3), 32.49 (tBu), 46.35 (C-5), 67.10 (C-2), 76.47 (C-1), 128.39, 129.58, 130.27, 133.07 (6 C, C6H5), 165.62 (C=0); HR-MS (ESI) m/z: calcd for C17H24Na03 [M+Na]: 299.1618; found: 299.1621 (1.0 ppm).
rac-E-V:1H-NMR (CDCI3, 500.1 MHz) 8: 0.89 (s, 9 H, tBu), 1.18 (m, 1 H, H-5a), 1.34 (m, 1 H, H-3a), 1.56 (m, 1 H, H-4), 1.83-1.98 (m, 3 H, H-5b, H-6), 2.04 (m, 1 H, H-3b), 4.25 (m, 1 H, H-2), 4.98 (ddd, 3J= 2.8, 4.9, 11.7 Hz, 1 H, H-1), 7.44-7.47, 7.56-7.59, 8.04-8.06 (3m, 5 H, C6H5); 13C-NMR (CDCI3, 125.8 MHz) 8: 25.07 (C-5), 25.27 (C-6), 27.48(3 C, tBu), 31.91 (tBu), 31.98 (C-3), 39.43 (C-4), 68.14 (C-2), 75.87 (C-1), 128.39, 129.58, 130.28, 133.06(6 C, C6H5), 165.72 (C=0); HR-MS (ESI) m/z: calcd for C17H24Na03 [M+Nar:
299.1618; found: 299.1621 (1.0 ppm).
rac-( IR,2R,4R)-2-(Benzoyloxv)-4-tert-butylcyclohexyl 3,5-dinitrobenzoate (rac-E-V1) rac-E-IV (400 mg, 1.45 mmol), triphenylphosphine (1.14 g, 4.33 mmol) and 3,5-dinitrobenzoic acid (921 mg, 4.34 mmol) were dissolved in toluene (25 mL). Diethyl azodicarboxylate (680 pL, 4.32 mmol) was slowly added to the reaction via syringe. The mixture was warmed to 50 C and stirred for 1 d. The solvent was evaporated in vacuo and the residue, redissolved in a small amount of CH2Cl2, was purified by MPLC on silica (petroleum ether/ethyl acetate, 10:0 to 10:1) affording rac-E-VI (428 mg, 63%) and recovered starting material rac-E-IV (103 mg, 26%) as white solids.

1H-NMR (CDCI3, 500.1 MHz) 5: 0.93 (s, 9 H, tBu), 1.25-1.47 (m, 3 H, H-3a, H-4, H-5a), 1.68 (m, 1 H, H-6a), 1.94 (m, 1 H, H-5b), 2.29-2.35 (m, 2 H, H-3b, H-6b), 5.27 (ddd, 3J = 4.9, 9.7, 11.4 Hz, 1 H, H-1), 5.35 (ddd, 3J =
4.7, 9.9, 10.5 Hz, 1 H, H-2), 7.36-7.39, 7.48-7.52, 7.96-7.98 (3 m, 5 H, C6H5), 9.06, 9.14-9.15 (2 m, 3 H, C6H3); 13C-NMR (CDCI3, 125.8 MHz) 8: 24.79 (C-5), 27.52 (3 C, tBu), 29.76 (C-6), 31.79 (C-3), 32.36 (tBu), 45.73 (C-4), 74.80 (C-2), 77.55(C-1), 122.31, 128.39, 129.44, 129.58, 129.74, 133.17, 133.81, 148.54 (12 C, C6H5, C6H3), 162.16, 165.89 (2 C=0); HR-MS (ESI) m/z: calcd for C24H26N2Na08 [M+Na]: 493.1581; found: 493.1582 (0.2 ppm).
rac-(1R,2R5R)-5-tert-Buty1-2-hydroxycyclohexyl benzoate (rac-E-VII).
rac-E-VI (135 mg, 0.287 mmol) was suspended in Me0H (5 mL).
Et3N (1 mL) was added and the reaction stirred for 1 h. The solvents were evaporated in vacuo and the residue was purified by MPLC on silica (toluene/ethyl acetate, 6:0 to 6:1) affording rac-E-VII (63.2 mg, 80%) as a white solid.
1H-NMR (CDCI3, 500.1 MHz) 5 : 0.88 (s, 9 H, tBu), 1.12 (m, 1 H, H-4a), 1.19-1.32 (m, 2 H, H-5, H-6a), 1.41 (m, 1 H, H-3a), 1.80 (m, 1 H, H-4b), 2.12-2.18 (m, 2 H, H-3b, H-6b), 3.69 (ddd, 3J= 4.9, 9.3, 11.3 Hz, 1 H, H-2), 4.88 (ddd, 3J = 4.7, 9.4, 10.7 Hz, 1 H, H-1), 7.43-7.46, 7.55-7.58, 8.06-8.07 (3 m, H, C6H5); 13C-NMR (CDCI3, 125.8 MHz) 6:24.89 (C-4), 27.54(3 C, tBu), 31.44 (C-6), 32.28 (tBu), 32.61 (C-3), 46.01 (C-5), 73.33 (C-2), 79.47 (C-1), 128.34, 129.64, 130.23, 133.05 (6 C, C6H5), 166.82 (C=0); HR-MS (ESI) m/z: calcd for C17H24Na03 [M+Na]: 299.1618; found: 299.1619 (0.3 ppm).
f(1R,2R,5R)-5-tert-Butv1-1-hydroxv-cyclohex-2-v112,3,4-tris-0-benzy1-6-deoxy-a- and 8-L-galactopyranoside (E-VIII) and f(1S,2S,5S)-5-tert-Butyl-1-hydroxy-cyclohex-2-yl] 2,3,4-tris-0-benzy1-6-deoxy-a-L-galactopyranoside (E-IX).
A mixture of rac-E-VII (76.9 mg, 0.278 mmol), A-VI (202 mg, 0.421 mmol), Bu4NBr (274 mg, 0.850 mmol) and powdered 4A molecular sieves (1 g) in CH2Cl2 (4 mL) and DMF (1 mL) was stirred at r.t. under argon for 3.5 h.
Then, CuBr2 (188 mg, 0.844 mmol) was added and the reaction mixture was Per/US2007/021541 stirred at r.t. for 11 h. The reaction mixture was filtered through celite and the filtrate was diluted with CH2Cl2 (30 mt.). The organic layer was successively washed with saki. aqueous NaHCO3 and brine (each 30 mL) and the aqueous layers were extracted with CH202 (3 x 40 mL). The combined organic layers were dried with Na2SO4, filtered and co-evaporated with toluene to dryness.
The residue was purified by MPLC on silica (petroleum ether/CH2C12/diethyl ether, 2:1:0 to 2:1:1) to afford the fucosylated diastereomers. To a stirred solution of these diastereomers in methanol/water (5:1, 6 ml), lithium hydroxide (200 mg) was added and the mixture warmed to 50 C. After stirring for 4 h the reaction mixture was diluted with CH2Cl2 (30 mL) and the organic layer was washed with brine (50 ml). The aqueous layerwas extracted with CH2Cl2 (3x 30 mL), and the combined organic layers were dried with Na2SO4, filtered and concentrated in yaw . The residue was purified by MPLC on silica (petroleum ether/ethyl acetate, 4:0 to 4:1) to yield E-VIII (72.1 mg, 44%, a.:13 =
1:0.12, yield over two steps) as an anomeric mixture and E-IX (63.0 mg, 38%, yield over two steps) as pure a-anorner.
.1321 j -41.3 (c =
0.31, CHCI3); 1H-NMR (CDCI3, 500.1 MHz) 8: 0.86 (s, 9 H, Su), 0.97-1.38 (m, 7 H, Fuc 11-6, H-411-4a111-5, H-68), 1.74 (m, 1 H, H-4b), 1.99-2.06(m, 2H, 11.=3b, H-6b), 3.22 (m, 1 H, H-2), 3.47 (m, 1 H, H-1), 3.70 (m, I H, Fuc 11-4), 3.94 (dd, 343,R = 2.4 Hz, 3..42,F3= 10.1 Hz, 1 H, Fuc H-3), 4.05-4.09 (m, 2 H, Fuc H-2, Fuc 11-5), 4.65, 4.66, 4.75, 4.82, 4.87 (5 m, 5 11, CH2Ph), 4.97-5.00 (m, 2 H, Fuc H-1, CH2Ph), 726-7.41 (tn, 1511, 3 C6H5); 13C-NMR (CDCI3, 125.8 MHz) 8: 16.65 (Fuc C-6), 25.17 (C-4), 27.55(3 C, tBu), 29.54 (C-3), 32.19 (tBu), 33.63 (C-6), 45.82 (C-5), 66.97 (Fuc C-5), 73.15, 73.33 (2 CH2Ph), 73.52 (0-1), 74.86 (CH2Ph), 76.16 (Fuc C-2), 77.41 (Fuc 0-4), 7921 (Fuc C-3), 84.09 (C-2), 96.33 (Fuc C-1), 127A0, 127A8, 127.64, 127.69, 127.90, 128.21, 128.35, 128.44, 138.41, 138.50,138.81 (18C, 3 C6113): HR-MS (ESI) mfr calcd for C34148Na06[114+Nar: 611.3343; found:
611.3346 (0.5 ppm).
*Trademark E-IX: [a]D21= -40.7 (c = 0.38, CHCI3); 1H-NMR (CDCI3, 500.1 MHz) 8: 0.85 (s, 9 H, tBu), 1.01-1.17 (m, 6 H, Fuc H-6, H-4a, H-5, H-6a), 1.29 (m, 1 H, H-3a), 1.70 (m, 1 H, H-4b), 1.97-2.04 (m, 2 H, H-3b, H-6b), 3.17 (m, 1 H, H-2), 3.45 (m, 1 H, H-1), 3.69 (m, 1 H, Fuc H-4), 3.96-4.05 (m, 3 H, Fuc H-2, Fuc H-3, Fuc H-5), 4.66, 4.73, 4.76, 4.81, 4.87, 4.97 (6 m, 6 H, CH2Ph), 4.98 (m, H, Fuc H-1), 7.26-7.41 (m, 15 H, 3 C6H5); 13C-NMR (CDCI3, 125.8 MHz) 8:
16.69 (Fuc C-6), 25.32 (C-4), 27.58 (3 C, tBu), 31.26 (C-3), 32.25 (tBu), 32.88 (C-6), 45.78 (C-5), 66.57 (Fuc C-5), 72.63, 74.19(2 CH2Ph), 74.66 (C-1), 74.80 (CH2Ph), 76.33 (Fuc C-2), 77.40 (Fuc C-4), 80.01 (Fuc C-3), 87.22 (C-2), 101.01 (Fuc C-1), 127.34,127.52, 127.58, 127.84, 128.18, 128.22, 128.34, 128.39, 128.47, 137.95, 138.53, 138.65 (18 C, 3 C6H5).
{(1R,2R,5R)-21(2,3,4-tris-0-benzy1-6-deoxy-a-L-galactopvranosvI)oxv1-5-tert-butyl-cyclohex-1-y1} 2,4,6-tri-O-benzoy1-3-04(1S)-1-benzyloxycarbony1-2-cyclohexvl-ethyll-13-b-dalactopyranoside (E-X).
According to general procedure C, thioglycoside A-Vl (125 mg, 0.161 mmol) and glycosyl acceptor E-VIII (71.4 mg, 0.121 mmol) in dry CH2Cl2 (4 mL) were added via syringe to activated 4A molecular sieves (1 g). A
suspension of DMTST (120 mg, 0.465 mmol) and activated 4A molecular sieves (500 mg) in CH2Cl2 (2 mL) was prepared in a second flask. Both suspensions were stirred at r.t. for 2 h, before adding the DMTST suspension via syringe to the other suspension with some additional CH2Cl2 (1 mL). The reaction was stopped after 45 h and worked-up according to general procedure C. The crude product was purified by MPLC on silica (toluene/ethyl acetate, 11.5:0 to 11.5:1) to yield E-X (107 mg, 68%) as a colorless foam.
[a]D21 -57.9 (c = 0.50, CHCI3); 1H-NMR (CDCI3, 500.1 MHz) 8:
0.46-1.43 (3m, 17 H, CyCH2, Cy), 0.58 (s, 9 H, tBu), 1.36 (d, 3J= 6.0 Hz, 3 H, Fuc H-6), 1.60 (m, 1 H, H-4b), 1.81 (m, 1 H, H-6b), 1.99 (m, 1 H, H-3b), 3.45 (m, 1 H, H-2), 3.55 (m, 1 H, H-1), 3.58 (s, 1 H, Fuc H-4), 3.87-3.90 (m, 2 H, Gal H-3, Gal H-5), 3.97-4.04 (m, 2 H, Fuc H-2, Fuc H-3), 4.16 (m, 1 H, Lac H-2), 4.29 (m, 2 H, Gal H-6), 4.39 (m, 1 H, CH2Ph), 4.55-4.57 (m, 2 H, Gal H-1, CH2Ph), 4.63 (m, 1 H, CH2Ph), 4.69-4.74 (m, 2H, CH2Ph), 4.794.83 (rn, 2 H, Fuc H-5, CH2Ph), 4.88 (d, 3.41,F2 = 2.1 Hz, I H, Fuc H-1),5.04, 5.13(2 m, 2 H, CH2Ph), 5.56 (m, 1 H, Gal H-2), 5.91 (m, 1 H, Gal 1-14), 7.17-7.35, 7.39-7.48, 7.54-7.55, 8.04-8.11 (m, 35 H, 7 C6F15); 13C-NMR (CDC13, 125.8 MHz) 8: 16.62 (Fuc C-6), 24.43 (C4), 25.40, 25.71, 26.06 (3 C, CyCH2), 27.19 3 C, fBu), 28.97 (C-3), 31.95 (tBu), 32.23 (C-6), 32.49, 3117, 33.44(3 C, CyCH2), 40.44 (CyCH2), 45.50 (C-5), 6221 (Gal C-6), 65.98 (Fuc C-5), 66.58 (CH2Ph), 69.86 (Gal C-4), 71.19 (Gal C-5), 72.53, 72.56 (Gal C-2, CH2Ph), 73.02 (CH2Ph), 74.90 (CH2Ph), 75.25 (C-2), 76.44 (Ric C-2), 77.51 (Gal C-3), 78.08 (Lac C-2), 79.24 (Fuc C-4), 79.64 (Fuc C-3), 81.37(C-I), 94.16 (Fuc C-1), 100.24 (Gal C-1), 126.87, 126.95, 127.22,127.38, 127.93, 127.95, 128.03, 128.15, 128.34, 128A2, 128A7, 128,50, 129.64, 129.74, 129.83, 129.88, 129.91, 13104, 133.16, 13321, 135.43, 138.86, 139.08, 139.14 (42 C, 7 C8H5), 164.56,165.65, 166.11, 172.47 (4 C=0); elemental analysis calcd (%) for C851-190018 (1307,56):
C 73.48, H 6.94; found: C 73.50, H 6.95.
(f1R.2R.5R1-5-tert-Butyl-24(6-deoxy-a-L-Qalactopyranosvi)oxvi-cyclohex-1-yll 2-0-benzovi-3-0-1(1S)-1-carboxy-2-cyclohexvi-ethyll-8-b-galactoovranoside (E-X1-, Fig. 7).
A mixture of E-X (102 mg, 77.9 pmol), Pd(OH)21C (49.4 mg), dioxane (3 mL) and water (0.75 mL) was hydrogenated under 4 bar at r.t. After 37 h TLC control indicated completion of the reaction and the mixture was filtered through celite anti evaporated to dryness. The residue was redissolved In methanol (5 mL) anri sodium methoxide (0.195 mmol in 255 pL !MOH) was added. After stirring at Lt. for 14 h the reaction was quenched by addition of acetic acid (23 pL). The mixture was concentrated in ;MOW and purified by preparative, reversed-phase HPLC to afford compound &XII (50.9 mg, 88%) as a white solid.
[0.1021= -93.2 (C: 0.91, Me0H); 11-1-NMR (Me0D, 500.1 MHz) 8:
0.60-0.77 (m, 5 H, H6a, CyCH2), 0.65 (s, 9 H, tBu), 0.84 (m, 1 H, H-48), 0.93 (m, 1 H, CyCH2), 1.01 (m, 1 H, H-5), 1.15 (rn, 1 H, H-30), 1.26 (d, 3../F5,r6=
6.6 *Trademark Hz, 3 H, Fuc H-6), 1.29-1.39 (m, 5 H, CyCH2), 1.43 (m, 1 H, CyCH2), 1.53 (m, 1 H, CyCH2), 1.60-1.66 (m, 2 H, H-4b, CyCH2), 1.95 (m, 1 H, H-6b), 2.05 (m, 1 H, H-3b), 3.33 (m, 1 H, H-2), 3.56-3.61 (m, 2 H, H-1, Gal H-5), 3.69-3.74 (m, 4 H, Fuc H-2, Fuc H-4, Gal H-3, Gal H-6a), 3.79 (m, 3JG6b,G6 = 6.9 Hz, 2JG6a,G6b =
11.3 Hz, 1 H, Gal H-6b), 3.91 (dd, 3JF3,F4 = 3.4 Hz,3JF2,F3 = 10.1 Hz, 1 H, Fuc H-3), 4.00 (m, 1 H, Gal H-4), 4.10 (dd, 3J2.9, 10.0 Hz, 1 H, Lac H-2), 4.67 (d, 3Jc1,G2 = 8.0 Hz, 1 H, Gal H-1), 4.77 (m, 1 H, Fuc H-5), 4.82 (d, 3.-/H,F2 =
3.8 Hz, 1 H, Fuc H-1), 5.36 (dd, 3,1q1,q2 = 8.0 Hz, 3.-/G2,G3 = 9.8 Hz, 1 H, Gal H-2), 7.49-7.52 (m, 2 H, C6H5), 7.61-7.64 (m, 1 H, C6H5), 8.10-8.12 (m, 2 H, C6H5);
13C-NMR (Me0D, 125.8 MHz) 8: 16.53 (Fuc C-6), 25.74 (C-4), 26.60, 26.82, 27.30 (3 C, CyCH2), 27.78 (3 C, tBu), 29.73 (C-3), 32.83 (tBu), 33.11 (CyCH2), 33.74 (C-6), 34.26 (Lac C-4), 35.12 (CyCH2), 42.76 (Lac C-3), 47.02 (C-5), 62.69 (Gal C-6), 67.38 (Fuc C-5), 67.99 (Gal C-4), 70.03 (Fuc C-2), 71.57 (Fuc C-3), 73.63 (Gal C-2), 73.96 (Fuc C-4), 76.02 (Gal C-5), 76.90 (C-2), 78.03 (Lac C-2), 81.57 (C-1), 83.17 (Gal C-3), 96.51 (Fuc C-1), 101.13 (Gal C-1), 129.74, 130.90, 131.70, 134.40(6 C, C6H5), 166.83 (C=0), 178.78 (COOH); HR-MS
(ESI) miz: calcd for C381-156Na014 [M--H]: 761.3719; found: 761.3723 (0.5 ppm).

((1R,2R,3S,5R)-2-RDEoxv-a-L-GALAcToPYRANosYL)oxY1-3,5-DIMETHYL-CYCLOHEX-1-YL) 2-0-BENZ0YL-3-0-R1S)-1-CARBOXY-2-CYCLOHEXYL-ETHYLH-D-GALACTOPYRANOSIDE SODIUM SALT (F-VI; FIG. 8) 1(1R,2R,3S,5R)-1-tert-Butvldimethylsilvloxy-5-hydroxymethyl-3-methvl-cyclohex-2-v112,3,4-tris-0-benzyl-6-deoxy-a-L-qalactopvranoside (F-I).
To a solution of X (137 mg, 0.191 mmol) in dry THF (2 mL) was added a solution of 1M LiAIH4 (667 IAL, 0.667 mmol) in THF at 0 C under argon over a period of 10 min. After 1 h the reaction was quenched with satd.
aqueous (NH4)2SO4 (0.5 mL) and stirred at r.t. for 1 h. Then the mixture was dried with Na2SO4, filtered and the solvent evaporated in vacuo. Column chromatography (petroleum ether/ethyl acetate, 6:1) of the residue gave F-I
(110 mg, 84%).
[a]D2 = -51.3 (c = 0.335, CHCI3); ESI-MS m/z: calcd for C41 H58Na07S1 [M+Na]: 713.38; found: 713.35.
1(1R,2R,3S,5R)-1-tert-ButvldimethvIsilvloxy-5-chloromethyl-3-methyl-cyclohex-2-yll 2,3,4-tris-O-benzy1-6-deoxy-a-L-galactopvranoside (F-II).
To a solution of F-1(105 mg, 0.152 mmol) in dry DCE (1.5 mL) under argon 1-chloro-N,N,2-trimethylpropenylamine (43 1_, 0.304 mmol) was added dropwise. After stirring for 45 min at r.t. the reaction was quenched with Me0H/25 /0 aqueous NH3 (1:1, 0.5 mL) and evaporated to dryness. Column chromatography (petroleum ether/ethyl acetate, 19:1) of the residue yielded F-(91 mg, 85%).
[aiD2o , _46.3 (c = 2.20, CHCI3); ESI-MS m/z: calcd. for C41H57C1Na06S1 [M+Na]: 731.34; found 731.42.
1(1R,2R,3S,5R)-1-tert-ButyldimethvIsilyloxy-3,5-dimethvl-cyclohex-2-yll 2,3,4-tris-0-benzv1-6-deoxv-a-L-galactopyranoside (F-III).
To a solution of F-II (89 mg, 0.125 mmol) and AIBN (21 mg, 0.127 mmol) in dry THF (1.5 mL) was added freshly distilled Bu3SnH (366 [LL, 1.38 mmol) via a syringe under argon. After stirring for 90 min at 90 C the mixture was cooled to r.t. and diluted in MeCN (5 mL). The solution was washed with hexane (5 mL) and the layers were separated. The hexane layer was washed with MeCN (2 X 5 mL). The combined MeCN layers were evaporated in vacuo and the residue purified by column chromatography (petroleum ether + 4%
ethyl acetate) to yield F-ill (60 mg, 71%).
raiD2o _43.6 (c = 1.28, CHCI3); ESI-MS m/z: calcd. for C41H58Na06Si [M+Nar: 697.97; found 697.47.

WO 2008/060378 PC111.1S2007/021541 1(1 R2R,3S.5R)-1-Hydroxv-3,5-dmethyl-cyclohex-2-v112.3.4-tris-0-benzyl-6-deoxy-a-L-qalactoovranoside A mixture of F-Ill (70 mg, 0.104 mmol), THF (1.5 mi.), AcOH (1.8 mi.) and 1120 (1.5 mL) was stirred for 4 h at 80 C. The mixture was cooled to r.t., neutralized with satd. aqueous NaHCO3 (approx. 14 mL), diluted with DCM
(15 mL) and washed with water (15 mL). The aqueous layer was then extracted with DCM (2 X 10 mL). The combined organic layers were dried with Na2804, filtered and evaporated to dryness. Column chromatography (petroleum ether/ethyl acetate, 81) of the crude product gave F-IV (40 mg, 68%).
[4520 =
-40 8 (C = 2.00, CHC13); ESI-MS adz: calcd. for C33H44Na06 [M+Nar: 583,30; found 583.18.
{(1R.2R.3S,5R1-2-E(2.3.4-tris-O-benzyl-6-deoxy-g,-L-gaIactopyrariostoxyl-3.5-dimethyl-cvclohex-1-yl) 2.4,641-0-benzov14-0-1(1 S)-1-berizyloxYcarbonv1-2-cyclohexvl-ethy11-6-o-cialactooyranoside (FAA
A mixture of F-IV (45 mg, 80.3 mop, A-VI (85 mg, 108 lend) and activated powdered molecular sieves 4A (1 g) in DCM (2 mL) was stirred at r.t.

under argon for 4 h. Then a pre-stirred mixture (4 h, r.t.) of DMTST (83 mg, 0.321 mmol) and activated powered molecular sieves 4A (200 mg) in dry49CM
(2 mi.) was added. After 24 h the reaction mixture was filtered over Celite and the filtrate was diluted with DCM (10 mL). The organic layer was washed with satd. aqueous NaHCO3 and brine (each 5 mL) and the aqueous layers were extracted with DCM (2 x 5 ml). The combined organic layers were dried with Na2SO4, filtered and evaporated to dryness. The residue was purified by column chromatography on silica gel (petroleum ether/ethyl acetate, 6:1) to yield F-V (63 mg, 62%).
[
= _47.0 (c = 2.11, CHCI3); ESL-MS adz: calcd. for cciD2o C781-186Na018 [M+Nar; 1301.58; found 1301.64.
*Trademark ii1F2,2FOS.5F0-24(deoxy-a-L-galactooyranosyl)oxv1-3,5-dimethyl-cyclohex-1-y1) 2-0-benzoy1-3-04(18)-1-carboxy-2-cyclohexyl-ethy11-13-o-galactopyranoside sodium salt (F-VI: Fia8.
A mixture of F-V (50 mg, 39.1 limo!), Pd(OH)2/C (27 mg, 10% Pd), dioxane (1.5 mL) and water (400 gt.).WEIS hydrogenated In a Parr-shaker at 5 bar. After 4 h the mixture was filtered over Celite and evaporated to dryness.

The residue was re-dissolved in Me0H (3 mt.) and Na0Me (97.8 pmol in 160 iL ivie0H) was added. After stirring at r.tfor 16 h the reaction was quenched with AcOH (10 pL), concentrated in vacuo and purified by preparative, reversed-phase HPLC. The freeze-dried product was re-dissolved in water and one equivalent of NaOH was added. The solution was lyophilized from water to afford F-Vi (23.3 mg, 80%) as a white solid.
[ceD2o =
I 89.0 (e = 1.16, H20); ES1-MS az: calcd. for C36H54Na014 [M+H]: 733.34; found 733.41.

SYNTHESIS OF COMPOUND G-IV (FIG. 12) Synthesis of intermediate GA Compound XXII (100 mg;
Example 2) was treated with 0.01N Na0Et in Et0H (2m1) 2h at room temperature, neutralized with AcOH and the solution was evaporated to dryness. The residue was purified by column chromatography to give G-II (47 mg).
Synthesis of intermediate G-111: Compound G-11(250 mg) was dissolved in climsine-water (10:1, 6.6 ml) and treated with 10% RUC under atmosphere of hydrogen for overnight. Solid was filtered off and filtrate was evaporated to dryness. The residue was purified by column chromatography (silica gel) to give compound G-111 (100mg).
Synthesis of compound G-IV: NH2OH. HCI (64 mg) was dissolved in H20 (0.5m1). To this solution was added a solution of NaOH (70mg) in 1420 (0.5m1). Compound 0-111 (25mg) in Me0H (0.5ml) was added to the above *Trademark solution with stirring at room temperature. The mixture was stirred at room temperature for 15 min and then neutralized to pH 7.0 by adding 1N HCI
solution. Solvent was evaporated off and the residue was purified by column chromatography (silica gel) to give compound G-IV.

SYNTHESIS OF COMPOUND H-IV (FIG. 13) Synthesis of intermediate H-II: Compound F-V (100 mg;
Example 8) was treated with 0.01N Na0Et in Et0H (2m1) 2h at room temperature, neutralized with AcOH and the solution was evaporated to dryness. The residue was purified by column chromatography to give H-I1 (55 mg).
Synthesis of intermediate H-III: Compound H-II (125 mg) was dissolved in dioxane-water (10:1, 6.6 ml) and treated with 10% Pd/C under atmosphere of hydrogen for overnight. Solid was filtered off and filtrate was evaporated to dryness. The residue was purified by column chromatography (silica gel) to give compound H-III (75mg).
Synthesis of compound H-IV: Compound H-III is treated in the same way as described for the synthesis of G-IV to give H-IV.

SYNTHESIS OF PEGYLATED MIMIC (FIG. 10) Synthesis of Second Compound of Fig. 10 First compound (100 mg) of Fig. 10 was mixed with ethylenediamine under the argon. The resulting mixture was heated at 70 C for 7 hr. After evaporation, the residue was purified on C-18 column to afford 55 mg second compound. Yield 68%

PEGylation of Second Compound of Fig. 10 Second compound (5 mg) was mixed with mPEG-nitrophenylcarbonate (5K) 75 mg , triethylamine 5 ul in DMF (2 mL). The resulting mixture was stirred at rt for 3 h. The solvent was removed at reduced pressure. The residue was purified on C-18 to afford 40 mg product.

SYNTHESIS OF TETRAMER PEGYLATED MIMIC (FIG. 11) Second compound (20 mg) from Example 11 was mixed with 200 mg 4-arm PEG glutamidylsuccinate , triethylamine 5 ul and DMF 2 mL. The resulting mixture was stirred at rt for 2 hr. After removing the solvent, the residue was purified on HPLC to afford the product.

E-SELECTIN ASSAY
E-selectin Protocol: The inhibition assay to screen glycomimetic antagonists of E-selectin is a competitive binding assay, which allows the determination of IC50 values. Briefly, E-selectin/Ig chimera is immobilized by incubation at 37 C in 96 well microtiter plates for 2 hours. To reduce nonspecific binding, bovine serum albumin is added to each well and incubated at room temperature for 2 hours. The plate is washed and serial dilutions of the test compounds are added to the wells in the presence of conjugates of biotinylated, sLea polyacrylamide with streptavidin/horseradishperoxidase and incubated for 2 hours at room temperature. To determine the amount of sLea bound to immobilized E-selectin after washing, the peroxidase substrate, 3,31,5,51 tetramethylbenzidin (TMB) is added. After 3 minutes, the enzyme reaction is stopped by the addition of H3PO4 and the absorbance of light at a wavelength of 450 nm is determined. The concentration of test compound required to inhibit binding by 50% is determined and reported as the IC50 value for each glycornirnetic E-selectin antagonist. In addition to reporting the absolute ICso value as measured above, relative ICso values are determined by a ratio of the ICso measured for the test compound to that of a glycomimetic internal control (reference) for each assay. The results from the testing in this assay of several of the compounds disclosed herein are shown below.
Compounds ICso (OM rliC50 #1 15,5 0.076 #2 10.1 0.049 #3 3,75 0.027 From the foregoing it will be appreciated that, although specific embodiments of the invention have been described herein for purposes of illustration, various modifications may be made without deviating from the spirit and scope of the invention.

Claims (7)

1. A compound of the following formula:

R1 = C1-C8 alkanyl;
R2 = H, C1-C8 alkanyl, -C(=O)OX where X is C1-C8 alkanyl, -C(=O)NH(CH2)n NH2 where n = 0-30;
R3 = -O-C(=O)-X wherein X is C1-C8 alkanyl or R4 =
where Q is H or a physiologically acceptable cation and where R9 is cyclohexane, and R10 is and R5 = L-fucose.

2. The compound according to claim 1 having the formula:

where Q is H or a physiologically acceptable cation, Me is methyl and Bz is benzoyl.

3. The compound according to claim 1 having the formula:
where Q is H or a physiologically acceptable cation, Me is methyl and Bz is benzoyl.

4. The compound according to claim 1 having the formula:

where Q is H or a physiologically acceptable cation, Me is methyl and Bz is benzoyl.

5. The compound according to claim 1 having the formula:
where Q is H or a physiologically acceptable cation, Me is methyl and Bz is benzoyl.

6. The compound according to claim 1 having the formula:

wherein Bz is benzoyl.

7. The compound according to claim 1 having the formula:
wherein Bz is benzoyl.